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ABSTRACT 
Alzheimer’s disease (AD) is the most common form of dementia leading to cognitive 
dysfunction and memory loss as well as emotional and behavioral disorders. It is the 6th 
leading cause of death in United States, and the only one among top 10 death causes that 
cannot be prevented, cured or slowed. An estimated 5.4 million Americans live with AD, 
and this number is expected to triple by year 2050 as the baby boomers age. The cost of 
care for AD in the US is about $200 billion each year. Unfortunately, in addition to the 
lack of an effective treatment or AD, there is also a lack of an effective diagnosis, 
particularly an early diagnosis which would enable treatment to begin before significant 
neuronal damage has occurred.  
Increasing evidence implicates soluble oligomeric forms of beta-amyloid and tau 
in the onset and progression of AD. While many studies have focused on beta-amyloid, 
soluble oligomeric tau species may also play an important role in AD pathogenesis. 
Antibodies that selectively identify and target specific oligomeric tau variants would be 
valuable tools for both diagnostic and therapeutic applications and also to study the 
etiology of AD and other neurodegenerative diseases. 
Recombinant human tau (rhTau) in monomeric, dimeric, trimeric and fibrillar 
forms were synthesized and purified to perform LDH assay on human neuroblastoma 
cells, so that trimeric but not monomeric or dimeric rhTau was identified as 
extracellularly neurotoxic to neuronal cells. A novel biopanning protocol was designed 
based on phage display technique and atomic force microscopy (AFM), and used to 
isolate single chain antibody variable domain fragments (scFvs) that selectively recognize 
the toxic tau oligomers. These scFvs selectively bind tau variants in brain tissue of human 
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AD patients and AD-related tau transgenic rodent models and have potential value as 
early diagnostic biomarkers for AD and as potential therapeutics to selectively target 
toxic tau aggregates.  
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Chapter 1 
Introduction 
1.1 Background and Introduction 
Alzheimer’s disease (AD) is the most common form of dementia resulting in the 
progressive neuronal and cognitive loss. About 5.4 million Americans suffer from AD 
and this number is expected to triple by 2050. It costs United States $200 billion annually 
including medication and care provision that doesn’t include the unpaid care valued $210 
billion given by more than 15 million Americans. AD is now the sixth leading cause of 
death in US and unfortunately is the only disease among the top ten death causes that 
cannot be prevented, cured or even slowed[1]. The current therapeutic approaches such as 
acetylcholinesterase inhibitor only treat symptom and not the underlying causes of the 
disease that remain elusive. AD is neuropathologically characterized by the presence of 
extracellular senile plaques containing aggregates of amyloid beta (Aβ) and intracellular 
neurofibrillary tangles (NFTs) containing aggregates of tau[2-3]. Increasing evidence 
correlates protein misfolding and aggregation of Aβ and tau with the pathogenesis of 
AD[4]. Normal tau plays an important role in assembling neuron microtubule and 
stabilizing its structure and physiological function while hyperphosphorylated tau 
oligomers and aggregates are diffuse from microtubule and likely responsible for synapse 
loss[5]. Therefore selectively targeting AD related forms of tau such as 
hyperphosphorylated and oligomeric forms of tau represents a promising diagnostic and 
therapeutic approach. One way to generate reagents against specific protein variants is to 
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pan for selected binding activities from surface display antibody libraries such as phage 
display library[6-8]. 
Single chain variable fragment (scFv) against tau oligomers is such a reagent. 
scFv is a fusion of one pair of heavy and light chain variable domains of immunoglobulin 
G (IgG)[9]. The lack of constant regions will greatly reduces the possibility of 
inflammation in scFv recipients in clinical tests[10]. The smaller molecular weight of 
around 29 kD facilitates scFv permeating blood-brain-barrier[11-12] before it’s 
compromised in the later stage of AD. ScFv only has one antigen-binding site specific to 
a single epitope on the antigen and its specificity is readily increased by affinity mature. 
To fulfill scFv screening, recovering and reproducing, we used Sheets phagemid library 
which is a human phage-displayed scFv library with complexity of 6.7×109 [9]. A phage 
clone from this phagemid clone is a filamentous M13-derived bacteriophage with a 
molecule of scFv expressed on its surface and linked with a g3p. It is easy to be identified 
with atomic force microscope (AFM) and infectious to common E. coli strains to 
facilitate genetic modification.  
We developed and performed a novel biopanning technique that combines the 
binding variety of phagemid scFv library and imaging capability of AFM[6-8] to obtain 
groups of scFvs that have specific tau target. One group of scFv clones is specific to 
trimeric tau which showed in lactate dehydrogenase (LDH) tests as the most toxic of all 
available tau species in our lab. After DNA sequence modification, F9T keeps specificity 
to oligomeric tau and displays efficient soluble scFv expression and purification. In 
preliminary human brain tests, F9T demonstrates the potential of discriminate AD from 
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ND on human middle temporal gyrus (MTG) tissue and human cerebrospinal fluid, both 
of which are affluent with abnormal tau in AD. Another group of scFv clones targets all 
types of small molecular tau such as monomer, dimer, oligomers regardless of their 
phosphorylated conditions.  
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Chapter 2  
Alzheimer’s disease (AD) and tau targeted therapeutic strategies 
2.1 Alzheimer’s disease 
Alzheimer’s disease is a progressive neurodegenerative disease. Patients suffering from 
AD experience memory loss and decrease in cognitive function. The long term medical 
care for AD patients not only costs US billions of dollars yearly, but also causes great 
emotional stress for their families. An estimated 36 million people worldwide live with 
AD, of which nearly 1/7 live in US. The number of people suffering from AD in the US 
is expected to triple by 2050 as the baby boomers age [1]. Unfortunately, there are still no 
effective treatments to prevent, hinder or reverse AD. Therefore, it is extremely crucial to 
develop reliable diagnostic approaches and effectual therapeutic strategies against AD.  
Apart from the symptoms of dementia such as cognition loss and mental and 
behavioral problems, AD patients display a series of noticeable anatomical alterations 
including brain volume and weight decrease, cerebral gyrus atrophy, neuron loss in 
specific brain regions such as hippocampus and entorhinal cortex,  and a progressive 
cortical thickness decrease which can be traced by MRI in multiple regions of AD brain, 
which associates with cognition decline and predicts the development from mild 
cognitive impairment (MCI) to AD[2-3]. Aberrant neural networking activities have also 
been observed in patients with AD [4]. Synapse and dendrite loss correlates better with 
cognitive loss than neuron loss does[5], therefore increasing acetylcholine levels by either 
acetylcholinesterase inhibitor or direct dosage of this neurotransmitter is an effective way 
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of temporarily ameliorating AD symptoms [6]. The use of acetylcholinesterase inhibitors 
is thus an approved clinical treatment for AD. 
Scientists have been investigating AD etiology for more than a century. While 
many aspects of the disease are still unknown due to the multiple complex interactions, 
some key factors contributing to the disease are known.  Genetic factors include 
mutations in the amyloid precursor protein (APP), presenilin-1 (PS-1) and presenilin-2 
(PS-2) genes causing early-onset automosonal dominant Alzheimer’s, however these 
mutations account for less than 1% of all AD cases[7-8]. Apolipoprotein E4, on the other 
hand, is semi-dominant inheritance for most of the familial and sporadic AD cases, and 
individuals with two copies of apoE4 alleles are more likely to develop AD, implicating 
ApoE4 as the most significant risk factor for AD[9].  
In addition to genetic factors, aberrantly folded and aggregated proteins have also been 
implicated in AD. The two distinct hallmarks of AD are the presence of extracellular 
senile plaques composed mainly of fibrillar aggregates of amyloid beta (Aβ) and 
intracellular neurofibrillary tangles (NFT) enriched with aggregates of abnormally 
hyperphosphorylated tau[10-11]. While these features were first found postmortem over a 
hundred years ago, they can now be traced in living patients using advanced radiological 
imaging techniques such as PET scanning[12]. Accumulating evidence suggest that an 
increase in Aβ levels contributes causally to AD development. Aβ regulates neuronal and 
synaptic activities and accumulation of Aβ in the brain causes a combination of aberrant 
network activity and synaptic depression[5]. Of particular interest, the aggregation state 
of Aβ is critically important as neither Aβ monomer nor insoluble Aβ fibrils found in 
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amyloid plaques is as pathogenic or toxic as soluble nonfibrillar Aβ assemblies such as 
dimer, trimer and other oligomer forms. Although it remains controversial which Aβ 
assemblies are the most toxic and how the Aβ assembly forms into insoluble aggregates 
and cause neuronal synaptic dysfunction, Aβ oligomers have been shown to have toxic 
interactions with several cell-surface molecules including the tyrosine kinase receptor 
(tkR) and the receptor for advanced glycation end product. Aβ oligomers may change the 
distribution and activity of neurotransmitter receptors and related signaling molecules, 
disrupt intracellular calcium homeostasis, and impair axonal transport and mitochondrial 
functions[12].  
Similar to the toxic role of oligomeric species of Aβ, oligomeric forms of tau are 
more toxic than monomeric or fibrillar tau aggregates[13-14]. Despite the toxic role of 
oligomeric Aβ and tau in AD, the presence of fibrillar Aβ aggregates and tau NFTs is 
used to corroborate AD in living patients, partly because we lack reliable tests to quantify 
soluble Aβ and tau oligomeric species in human brain tissue. Development of such tests 
is important because they may enable a better correlation of cognitive impairment with 
levels of selected toxic oligomers, provide a means of monitoring the effect of drugs on 
lowering the levels of related toxic oligomers in AD afflicted brain sections during 
clinical trials, and provide an earlier diagnosis of AD. While several reagents have been 
developed to target different oligomeric Aβ species, very few have been developed to 
target oligomeric tau.  
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2.2 Tau’s role in AD and treatment targeting tau 
Tau is a microtubule-associated protein (MAP) which was first identified as a crucial 
factor in assembly and stabilization of microtubule in the mid 1970s[15-16] and later in 
signaling pathways[17]. Despite of the multiple roles of tau in neuronal physiology, 
hyperphosphorylated tau is a major component of the insoluble filamentous neurofibillary 
tangles (NFTs) of Alzheimer’s disease. All neurodegenerative diseases with abnormal tau 
inclusions are termed as tauopathies, including AD, progressive supranuclear palsy (PSP), 
frontotemporal lobar degeneration with tau inclusions (FTLD-tau) such as Pick’s disease 
and genetic forms of Parkinson’s disease[18]. The complete in vivo function and the role 
in pathogenesis of tau remain elusive. Some of the cellular functions of tau such as 
microtubule stabilization overlap with the function of other MAPs since tau knockout 
mice display no functional impairment or shortened longevity[19].  While the presence of 
abnormal tau aggregates in Alzheimer’s suggests the association with pathology, this 
does not prove a cause-effect relationship.  
The human tau gene is encoded on chromosome 17q21 with at least 16 exons[20]. 
By alternative splicing on exon 2, 3 and 10 of tau mRNA, tau is known to exist in six 
isoforms in human brain[21]. Many tau gene mutation sites have been related to 
tauopathies including AD. Tau also undergoes multiple posttranslational modifications 
such as phosphorylation of serine and threonine residues that can regulate tau function. 
Evidence suggests that 4R tau is more prone to be hyperphosphorylated than 3R tau[22],  
which makes 4R tau a favorable target to treat AD. Tau found in paired helical filaments 
(PHF) autopsied AD brain tissue has 3 to 4 times higher phosphorylation levels compared 
to normal tau[23-24].  
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Since tau hyperphosphorylation is related to AD pathology, reagents have been 
developed to inhibit tau phosphorylation including inhibitors of kinases such as GSK-3β 
and cdk5[25]. A major drawback to kinase inhibitors is that they disrupt the normal 
functions of kinases. For example, the reduction of GSK-3β impairs NMDAR-mediated 
long-term depression[26] and memory consolidation[27]. Tau aggregation inhibitors are 
also being developed along with other amyloidosis inhibitor to reverse the formation of 
NFT. Many drugs that inhibit tau aggregation may have the similar benefits towards 
multiple pathological targets including Aβ and α-synuclein[28]. While promising, it is far 
from certain that the insoluble aggregated tau is actually toxic and responsible for tau-
dependent neuron loss and neurodegeneration. One unexpected effect of tau aggregation 
inhibitor may be to enhance the formation of soluble tau oligomers[29] which are 
potentially neurotoxic[13, 30] and can form during the early stages of tau aggregation in 
AD[31]. This potential side effects strongly underline the importance of treatments 
targeting toxic tau oligomers instead of filamentous aggregates. Reagents that are able to 
selectively inhibit tau-tau interactions, or oligomer formation and not just inhibit fibrillar 
aggregation are needed. Assuming ongoing experiments confirm that reduction of overall 
tau levels is safe and beneficial for ameliorating the cognition of patients, tau can be 
either directly targeted by reagents or be reduced indirectly by targeting molecules that 
regulate the expression or clearance of tau. Either way, reagents such as antibodies or 
antibody fragments that can selectively bind individual protein morphologies can be very 
useful.  
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2.3 Antibody based therapeutics for Alzheimer’s disease 
Active and passive immunization with full length antibodies against different regions and 
forms of Aβ have demonstrated great potential in clearing Aβ and reversing AD related 
cognition impairment in animal models although clinical trials in humans have been less 
encouraging and have led to side effects including inflammation[32] and micro-
hemorrhaging. Single chain variable fragments (scFv) which contain only the antibody 
binding domain are a promising route to overcome inflammation issues. ScFvs are 
composed of variable regions of full size antibodies to form one specific binding site 
which retains the binding specificity of the full antibody. Since the scFvs lack the 
antibody constant region responsible for the inflammatory response, scFvs can have 
selective advantages over active immunization strategies for a range of in vivo 
applications[33]. ScFvs have already shown promise as interventional reagents targeting 
pathogenic features in cancer[34]. ScFv genes can be engineered into the genome or 
plasmid of bacteria, yeast or even plant systems for efficient expression[35]. A typical 
scFv molecular weight is around 29kDa which is only about 1/6 of the full 
immunoglobulin size. This is a potential advantage for facilitating penetration of blood 
brain barrier (BBB) that guards the brain from large non-lipid-soluble interstitial 
particles[36]. Due to their small size, low level of kidney uptake and efficient blood 
clearance, scFvs are increasingly used as an in vivo carrier of radionuclei and drugs as 
well[37]. ScFvs can be readily affinity matured to obtain higher binding specificity and 
affinity to its target[38]. In summary, scFv based therapeutic strategies represents a 
promising way of understanding pathogenesis of diseases including Alzheimer’s and 
treating AD by interacting with amyloid misfolded forms and featured aggregates. 
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2.4 Research objectives and hypotheses 
Alzheimer’s disease is a progressive neurodegenerative disease resulting in memory loss 
and cognitive impairment. AD is characterized by the presence of two hallmark 
pathological features, Aβ senile plaques[39] and tau neurofibrillary tangles[10]. While 
the amyloid cascade hypothesis which states that accumulation of Aβ is a primary factor 
in the onset of AD has strongly influenced the direction of AD therapeutic development 
for over a decade[5, 40-42], because tau now has also been shown to play a critical role 
in AD [43-46] therapeutics targeting tau are drawing increasing interest. Normal 
monomeric tau functions in healthy neurons as a microtubule-associated protein[15-16]. 
When it becomes hyperphosphorylated tau does not bind microtubules and is more prone 
to misfolding and aggregation[18, 47]. While current reagents can detect total tau and 
certain hyperphosphorylated tau levels, it is not clear that these forms are the most 
relevant tau forms correlated with AD. Therefore, reagents that can selectively target 
additional tau isoforms, in particular neurotoxic tau forms are critically important. The 
long term goal of our lab is to develop recombinant antibody fragment that can be an 
effective and safe part of diagnostic, preventive and therapeutic approaches to 
neurodegenerative diseases such as Alzheimer’s. To achieve this goal, we have been 
using single chain variable fragment (scFv) to target pathological AD species. We have 
already developed scFvs against various forms of Aβ[48-51], its precursor APP[38, 52] 
and against the protein α-synuclein[53-54] implicated in Parkinson’s disease. We have 
shown that targeting oligomeric Aβ or α-synuclein can effectively reduce cytotoxicity 
and have promise both as therapeutic and diagnostic reagents. We have developed a 
novel biopanning process that combines the binding diversity of a phage display scFv 
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library with the powerful imaging capabilities of atomic force microscopy (AFM) for the 
purpose of monitoring antigen-antibody interaction[55]. This novel biopanning protocol 
enables us to isolate scFvs to antigen targets using nanogram amounts of target or less, 
even down to a single molecule. 
2.5 Introduction to related techniques 
2.5.1 Phage display library construction and functions 
The traditional monoclonal antibody development including immunization of animal[56] 
and hybridomas technology encountered a bottleneck of unwanted immune response 
elicited by the immunized animal monoclonal antibodies, restriction to a group of 
particular natural antibody isotypes, poor immunogenicity of certain targets and general 
issues associated with the full length antibody expression[33, 57]. On the contrary, phage 
display technique provides a powerful tool of screening monoclonal single chain variable 
fragment (scFv) from a scFv library against a wide array of antigen targets. The scFv 
library was designed and created from natural human antibody repertoires[58-59] 
therefore the resulting scFvs should be safe for human applications.  
The phage display library used in this study is based on genetic engineering of 
coat proteins of filamentous bacteriophages of Escherichia coli such as M13[59]. During 
phage propagation, the phage is elongated by the polymerization of major geneVIII and 
in the end capped by the terminal geneIII protein. By genetic fusion of geneIII with a 
particular peptide sequence (such as single chain variable fragment), we can expect this 
peptide expressed and displayed on the end of the phage along with geneIII protein. 
There are two ways of implementing this genetic fusion. One is by direct engineering of 
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the phage genome. The other is to incorporate scFv sequence into a geneIII-expressing 
plasmid combined with a helper phage system. The phage library used for screening scFv 
against AD-associated proteins is constructed by the latter method. It is human scFv 
repertoire phagemid library in TG1 bacteria. To express scFv phage, it requires VCSM13 
helper phage. Typically, it produces and secretes scFv into the E.coli periplasm where 
scFv remains at a high level. 
2.5.2 Atomic force microscope (AFM) and its application in tau size analysis 
and biopanning 
Atomic force microscope (AFM) is a relatively new and perhaps the most versatile 
member of a microscope family named scanning probe microscopes (SPM). Different 
from the conventional optic microscopes well-known to most people, SPM generates 
images by ‘touching’ and ‘feeling’ instead of ‘looking at’ samples. It’s similar to reading 
Braille or a blindfolded man touching an object and forming in the mind an image of its 
shape and size. SPM sense the structure of a surface by scanning it with a nano-scaled 
sharp probe and measuring some form of interaction between the surface and the probe. 
In AFM, the interaction detected is the vertical (z direction) displacement of probe due to 
intermolecular force change between probe and sample. The most common detection 
method is laser beam deflection. As shown in the schematic diagram in Figure 2.4, the 
probe-sample interaction is preset at a certain value. A laser beam is adjusted on the tip 
end of the probe and reflected onto a photo detector, which usually is a photodiode. As 
the probe raster scans along the sample in one dimension (x direction), the sample surface 
feature will change the probe-sample interaction causing an extension or deflection on the 
tip. This tip extension or deflection will be magnified by the displacement and intensity 
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of laser beam received by photo diode. A vivid analogy would be that of a naughty pupil 
sitting in the back of a classroom trying to dazzle the teacher by reflecting the sunlight 
through his watch face. The tiny movement of the watch can cause a large change of the 
light path and thus position the light spot to the teacher’s face. The change of laser 
position and intensity is captured by a photo diode. It transforms the received signal into 
electrical signal that triggers the feedback loop to notify the piezoelectric scanner to make 
adjustments to the sample vertical position in order to keep the preset value for probe-
sample interaction. This series of scanner adjustment is recorded along the raster scan. 
After one line is scanned, the probe starts an adjacent line scan until the whole appointed 
area is scanned.  
The AFM image is obtained using height mode which is analogous to a contour 
map. The particle height range is scale by color gradient in which darkest brown 
represents the baseline level and white as z values of 10 nm or higher. The particle 
horizontal size is represented by the pixels on the image. We use freshly cleaved mica as 
our sample carrier for its special layered structure that appears flat in angstrom-scale 
under AFM image. Monomeric tau size is about 43 kDa for 1N4R and 46 kDa for 2N4R, 
while scFv size is around 29 kDa. When imaged by AFM, these tau particles appear as 
white dots of various sizes on a brown background. The fibril and the phage are 
filamentous objects with a noticeable width difference. 
The mica is naturally negative charged thus can retain any protein that contains a 
positive group and repel any negatively charged particles such as bacteriophage. Its 
surface can be chemically treated for the special purposes such as holding certain objects. 
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In our case, we use natural mica during biopanning process in order to ensure that phage 
retain on the mica surface only due to the paratope-epitope interaction not due to static 
electric force.  
To prepare a sample for imaging, a 10µl aliquot of tau dissolved in 50mM Tris 
buffer was deposited on freshly cleaved mica and incubated at room temperature for 10 
minutes. Additional DI water was applied as necessary to moisturize the mica surface to 
prevent the salt in the buffer from crystallizing on the mica surface. To avoid 
contamination, the whole sample preparation process is recommended to be performed in 
a dust-free air-circulated biosafety cabinet. After the incubation, the mica was rinsed 
thoroughly with autoclaved filtered DI water and dried with pressured nitrogen air flow. 
Any new sample should be imaged in a series of dilutions to have a general idea of its 
density condition on AFM image. The proper sample concentration for AFM imaging 
depends on the purpose of the imaging and antigen availability. As stated previously, 
M13 phage cannot stay on untreated mica surface due to the negative surface charge 
while its display scFv can bind to its specific target immobilized on the mica. To check 
the morphology of phage, a 10 µl aliquot of the Sheets library phage in phosphate buffer 
saline (PBS) was deposited on a piece of tau-coated mica and washed after 10 minutes 
with 0.1% Tween20/DI water to remove all non-specific binding or phage trapped by 
large salt particles. Afterwards, the mica was rinsed with DI water to remove the residual 
unbound phage and Tween.  The mica was then dried with pressured nitrogen flow.  
AFM is particularly useful for differentiating biomolecules according to their 
shapes and sizes. Figure 2.5 is a typical AFM image demonstrating the morphological 
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features of tau monomer, oligomers, fibrils and scFv displayed bacteria phage. Tau 
monomer and low degree oligomers can be deemed as nanoscaled spherical particles that 
appear like fine salt or sand on AFM while tau fibrils and tangles are thick filamentous 
objects on AFM. One can also differentiate amyloid fibril from a M13 family phage by 
their distinctive width difference as shown in Figure 2.5. It requires software for image 
process and analysis to further distinguish scFv or scFv binding antigen from antigen by 
size distribution analysis addressed later in this section. Additionally, the scFv cannot be 
recovered and replicate itself. On the other hand, the scFv-display phage can be identified 
by AFM easily. Because a phage clone displays a reactive scFv on its end, the antigen-
antibody complex is located on the tip of the filamentous phage captured by AFM as 
shown in Figure 2.5 the filamentous object spot by a blue arrow. Besides, the spot phage 
can be collected by AFM probe and replicated following normal phage production. 
Therefore, scFv displayed phage is a desirable replacement for soluble scFv during 
panning process for AFM to detect antigen-antibody interaction. 
We can also use AFM to monitor the polymerization and aggregation process of 
amyloid because of this powerful capability. We performed the thioflavin T (ThT) 
fluorescence assay to monitor beta amyloid (Aβ) aggregation. ThT is a type of 
fluorescent dye that combines with protein beta sheet in direct proportion to its molecular 
weight. The fluorescent intensity of the complex is detected and compared with 
calibration chart for Aβ oligomer or aggregates molecular weight and thus the 
aggregation degree is known. Despite of its precision, ThT fluorescence assay is time-
consuming and restricted to β-sheet structured protein. Contrarily, AFM can image and 
identify easily all types of protein morphologies as shown in Figure 2.5 and Figure 2.6. 
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Generally, we investigate amyloid oligomerization and aggregation by incubate in room 
temperature or 37°C multiple aliquots of amyloid monomers in proper buffer and set the 
starting day as day 0. On each of the following days of interest, one aliquot of amyloid is 
transferred from the incubator into the freezer. After completing the aggregation time 
frame, all aliquot of amyloid at different stages of oligomerization and aggregation are 
deposited on multiple pieces of mica for AFM image. Figure 2.6 shows the AFM images 
of different morphologies of α-synuclein from globular monomer, larger grainy oligomer, 
rod-like protofibril and filamentous fibrils. The AFM image results showing Aβ 
ascending size and apparent fibril elongation is in line with the aggregation process. 
2.5.3 Particle size distribution analysis based on AFM imaging  
AFM technique is a powerful tool for imaging protein molecules (e.g. amyloid, antibody 
fragment and bacteriophage) for their quaternary structure in air or liquid with great 
precision. To image tau, we used two rhTau stocks available in our lab, 1N4R and 2N4R 
tau isoforms. They have been separated from the oligomer mixture and purified into 
monomer, dimer, trimer. On AFM images, tau molecules absolute size, its isoforms size 
difference and oligomer size difference are not perceivable by naked eyes but can be 
detected and analyzed with AFM image process and analysis softwares including SPIP, 
Gwyddion and Nanoscope.  
First the height of a series of oligomeric degree tau morphologies is measured to 
generate a calibration chart. One cannot avoid noise on AFM image of even the most 
purified sample because it is dissolved in Tris buffer that contains salt and the preparation 
in a low dust level environment doesn’t guarantee dust free. Therefore it is reasonable to 
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calculate the middle size range of the majority of particles. In this way, we not only 
eliminate background noises, but exclude small particles like salt and large grain like dust 
as well. In order to obtain the mean value of the molecular size of new stock of sample, 
one can prepare it on mica as described and take AFM images of 20 µm2 and zoom in to 
take representative images of 5 µm2 or 2 µm2 where the protein coating appears uniform 
without outstanding large objects. The software detects all the particles, records the 
particles’ heights as their molecular sizes and sorts them in ascending order. We can sum 
up total counts of particles of continuous interval sizes and calculate the percentage 
counts of each size range. Table 3.1 is a representative size distribution analysis result of 
various tau morphologies. We can see it is in accordance with the valid assumption that 
tau 2N4R of the higher molecular weight is larger than tau 1N4R at the same 
polymerization degree and that the higher degree oligmer is larger than the lower ones 
and the monomer. With this calibration chart, we can perform the similar AFM imaging 
and analysis on any tau samples either purified or mixed oligomers in order to 
corroborate its polymerization degree or indentify a specific particle in interest.  
2.5.4 scFv expression and purification  
The phage displaying scFv on its surface can readily infect bacteria facilitating their 
recovery and amplification. Together with the phage shell protein genome, the phage 
injects the bacteria with the scFv encoded plasmid. Soluble scFv expression is induced 
and regulated by lac operon from an E.Coli strain HB2151. The bacteria with plasmid 
encoding scFv proliferate rapidly in 2xYT media with glucose. At this stage, a high 
density of bacteria is desirable while scFv expression is suppressed. It is analogous to 
purchase machines for a factory in the first step. After the glucose in media is depleted, 
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isopropylthiogalactoside(IPTG) is added to induce the lac operon to start scFv expression. 
This is when the machines in the factory start to make products. The location and the 
concentration of scFv depend on the incubation temperature and duration. The scFv 
expressed in inclusion body is inactive and vulnerable to lysozyme. The soluble scFv, on 
the contrary, is excreted into periplasm in most cases. For certain clones or the longer 
incubation, considerable proportion of scFv will pass through the outer membrane into 
the culture media. All portions of bacteria, culture supernatant, periplasm and lysate, 
should be collected and concentrated for newly screened clones to investigate scFv yield 
and location by SDS-PAGE and western blot.  
The expressed scFv is fusion with N-terminal hexahistidine (6×His) tag for 
purification purpose. The concentrated portion is run through a nickel-charged beads 
affinity column that interacts with 6×His tag with micromolar affinity. On the other hand, 
non-specific proteins go through the column with flow-through or stringent wash. The 
scFv protein bound on the nickel column is displaced by competitive ligand of imidazole 
and eluted off for dialysis. The purified scFv is the reagent for tissue affinity test, 
neurotoxicity test and aggregation inhibition effects. 
2.5.5 Material and Methods 
Soluble scFv expression and confirmation- The complete corrected scFv gene are 
confirmed and then cleaved and ligated into pIT2 which tails on scFv N-terminal with c-
myc tag, 6×His tag and with the Amber stop codon. Amber codon is mute in TG1 E.coli 
strain facilitating phage expression, while activated in HB2151 E.coli strain enabling 
soluble scFv expression. The clone HB2151 transfected with scFv encoded pIT2 vector 
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grow in 37 ºC shaker overnight in 2xYT media with 100 µg/ml Ampicillin and 2% 
glucose. On the following day, overnight culture is used in 1/100 volume ratio to 
inoculate a large scale media of 2xYT with 100 µg/ml Ampicillin and 0.1% glucose. 
Glucose can greatly enhance the proliferation rate of bacteria and suppress scFv 
expression at this stage. The culture is incubated in 37 ºC grow until its optical density at 
600 nm (OD600) goes beyond 0.8, which means the glucose in the media is depleted thus 
the suppression to the lac operon is off. The scFv expression is triggered by the inducer 
isopropylthiogalactoside (IPTG) of 1 mM and kept in 30ºC shaker overnight.  
On the third day, the bacteria are spun down at 8000g for 30min. The supernatant 
is collected and concentrated on ice through 10 kDa molecular weight cut-off membrane 
(Millipore) using tangential flow filter (TFF). The periplasm in which the excreted scFv 
usually lies is extracted from the bacteria pellet. The pellet is first completely dissolved in 
TSE buffer (30mM Tris-HCl pH 8, 20% sucrose, 1 mM EDTA) of 1/20 culture volume 
and incubated on ice for 20 min. The mixture is then centrifuged without brake for 30 
min 5000g and divided with caution supernatant and pellet which are dissolved separately 
in equal volume of PBS. Another 20 min ice incubation and 10,000g 20 min centrifuge 
with brake is performed. The ‘supernatant’ portions collected from both parts are 
combined as the periplasm of the culture. The remaining cell pellet is incubated on ice for 
1.5h in 1 ml/mg lysis buffer containing lysozyme and protease inhibitor PMSF at the 
volume of 5 ml per 1 g pellet. The bacteria mixture is vortex for thorough lysis and 
centrifuged to separate lysate and cell debris. At this point of time, three major portions 
are obtained and their protein constituents are by MW on sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE). The samples are mixed with twice 
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volume of loading buffer (19:1 of Laemmli sample buffer:β-mercaptoethanol). All mixed 
samples are incubated in a boiling waterbath for 10 min when β-mercaptoethanol reduces 
the disulfide bonds and interrupt the proteins tertiary structure and the quatenary structure. 
The samples are run in duplicates of which one is stained by Coomassie Brilliant Blue R-
250 (Figure 2.8a) and the other is transferred onto nitrocellulose membrane for western 
blot (Figure 2.8b). The transferred membrane is blocked with 5% fat-free milk in PBS 
and incubated in room temperature for 2 hour each with 9E10 anti-cmyc produced in 
mouse and anti-mouse HRP-conjugated antibody produced in goat successively. After 
each step of high-specificity antibody probing, thorough rinse is mandatory. HRP can 
react with the 3,3’-diaminobenzidine(DAB) to display chromogenic signal. 
 
Soluble scFv purification- After confirming the presence of scFv in supernatant, 
periplasm and/or lysate of expression culture, load the total volume of each portion (e.g. 
periplasm) a Ni-NTA agarose beads column (Qiagen,5mL beads for 1L expression 
culture) in 4 ºC and allow it go through the column driven by gravity. The column is then 
stringently washed with 0.1% Tween20/2×PBS. The flow-through and the wash are 
sampled and kept lest loss of scFv. The imidazole eluting buffer is loaded on the column 
in the order of increasing concentration of 50 mM, 100 mM, 200 mM and 1M 
imidazole/2×PBS. The 1M imidazole elutes off all the rest of protein staying on the 
column. For the first purification trial, each elute along with flow-through and wash 
samples are dispersed on SDS-PAGE and performed Western blot to estimate the scFv 
concentration and purity. After the first time, the imidazole concentration that elutes off 
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only and most scFv will be selected as the specific concentration for eluting a certain 
scFv clone.  
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2.6 Figures and Tables 
 
Figure 2.1 Schematic basis of Alzheimer’s disease pathogenesis[12]. The neuritic amyloid plaque usually lies 
extracellular while the tau neurofibrillary tangles can be spot both intracellular detached from microtubule or 
extracellular after neuronal necrosis. 
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Figure 2.2 Schematic of tau structure, function and possible location[17]. Tau2N4R in the figure is the longest 
possible isoform. Total six tau isoforms are created by alternative splicing on N terminal exon 2, 3 (N1, N2) and C-
terminal microtubule-associated repeats with the presence of absence of exon 10 (3R or 4R). 
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Figure 2.3 Schematic monoclonal scFv display phage particle with phagmid DNA (magnified) encoding scFv and 
the terminal protein III[60]. After the scFv encoded plasmid host bacteria are infected by M13 family helper phage, 
they take up phage shell protein gene to express and package them together with scFv. The new generation of phage is 
a different type with the scFv (red) displayed on its surface as a fusion with the terminal phage gene III protein (a.k.a 
g3 protein, green). They contain a phagmid DNA (magnified) and expressed both scFv and g3 protein from the same 
promoter. 
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Figure 2.4  Schematic of AFM working principle. 
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Figure 2.5 AFM image of tau 441 fibril (rod shaped object pointed with a black arrow), bacteriophage of F9T 
clone (filamentous object pointed with a blue arrow) and tau oligomers with various sizes and location either on 
one end of the phage or scattered in the background (white dots on the background). 
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Figure 2.6 AFM can distinguish different size and morphology of α-synuclein from small globular protein 
monomer, grainy oligomer, rod-like protofibril and long thick fibril. These AFM images directly demonstrate α-
synuclein oligomerization and aggregation process. 
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Figure 2.7 Schematic principle of 6-his tag ligated protein purification through nickel charged affinity column.  
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Figure 2. 8 scFv expression and its distribution in culture supernatant, periplasm and cell lysate. The SDS-PAGE 
(a) demonstrates scFv purity and the other ingredients molecular weights. The western blot (b) confirmed the presence 
of scFv by detecting cmyc tag on the scFv at its corresponding molecular weight around 29kDa.   
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Chapter 3 Trimeric tau is toxic to human neuronal cells at low nanomolar concentrations 
3.1 Abstract 
Tau in its monomeric form facilitates polymerization of tubulin into microtubules and 
helps to maintain their structure in neuronal axons.  In Alzheimer’s disease (AD) the 
hallmark neurofibrillary tangles (NFTs) contain aggregated tau in a hyperphosphorylated 
form. Although hyperphosphorylated tau and NFTs have long been considered as key 
pathological features of AD, soluble oligomeric tau species may play a more critical role 
in AD progression since these tau species correlate better with neuronal loss and 
cognitive dysfunction. Recent studies show that extracellular oligomeric tau can inhibit 
memory formation and synaptic function and also transmit pathology to neighboring 
neurons, however the specific forms of oligomeric tau involved in toxicity are still 
unknown. Tau naturally exists in six major isoforms due to post-transcriptional splicing 
and also undergoes various post-translational modifications including phosphorylation, 
all of which greatly complicate studies to determine which tau aggregates are neurotoxic. 
Recombinant human tau can be generated in single splice variants and without post-
translational modification facilitating such studies. Here we used two different splice 
variants (1N4R and 2N4R) of non-phosphorylated recombinant human tau (NPrhTau) 
and generated monomeric, dimeric and trimeric fractions of each isoform. The 
composition of each fraction was verified chromatographically and also by atomic force 
microscopy (AFM). The toxicity of each fraction toward both human neuroblastoma cells 
37 
and cholinergic-like neurons was assessed using a lactate dehydrogenase (LDH) assay. 
Trimeric but not monomeric or dimeric tau aggregates of both splice variants was 
neurotoxic at low nanomolar concentrations, with the full length tau isoform having 
increased toxicity compared to the truncated tau variant.  
3.2 Introduction 
Alzheimer’s disease (AD) is the most common form of dementia, characterized by 
progressive cognitive impairment, cerebral atrophy and neuronal loss, with death 
generally occurring four to eight years after diagnosis[1]. Two pathological hallmarks of 
AD, extracellular neuritic plaques primarily composed of amyloid beta (Aβ) and 
intracellular neurofibrillary tangles (NFTs) primarily composed of tau protein, were 
originally identified in 1906 by Dr. Alois Alzheimer[2]. While great strides have been 
made in understanding the mechanisms that promote aggregation of Aβ and tau into the 
hallmark plaques and tangles, comparatively little progress has been achieved in halting 
or curing the disease.  Analysis of familial AD cases implicated production of Aβ as a 
primary factor in progression of AD, leading to the rise of the amyloid cascade 
hypothesis which states that Aβ misfolding and aggregation initiates AD pathogenesis 
and triggers other effects such as tau phophorylation, aggregation and tangle formation 
[3]. The amyloid hypothesis had dominated the field for more than a decade, and has 
driven numerous clinical studies for therapeutic interventions including several 
immunization studies targeting Aβ[4-6]. However failure of several clinical trials 
targeting Aβ has cast doubt on the pathological role of Aβ in AD [7], and increasing 
evidence indicates that tau also plays an important role in the progression of AD. Tau 
misfolding and aggregation can take place independently of amyloid formation[8], and in 
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many cases the presence of tau lesions are associated with AD without presence of Aβ 
aggregates[9]. Clearance of Aβ plaques without reducing soluble tau levels is insufficient 
to ameliorate cognitive decline in double transgenic mice overexpressing Aβ and tau 
P301L[10].  These results among many others indicate that oligomeric tau may be an 
important therapeutic target for AD. 
Tau in its monomeric form is a microtubule-associated protein crucial for 
microtubule assembly [11-12] and stabilization [13].  Six major tau isoforms can be 
generated by alternative posttranscriptional splicing of exon 2 and exon 3 on the N-
terminal projection domain and of exon 10 (Repeat 2) on the assembly domain (Figure 
3.1).  Tau contains three or four similar but not identical repeats on the microtubule-
binding domain (MBD) that binds to and helps promote microtubule stability and 
function. For example, Repeat 2 and Repeat 3 contain hexapeptide motifs of PHF6* and 
PHF6 respectively (Figure 3.1). These motifs increase the tendency to form β-sheet 
structures that can interact with tubulins to form microtubules and also facilitate self-
assembly to generate oligomeric and higher-order aggregates[14-15]. Tau isoforms with 
or without the second microtubule binding repeat can aggregate, but only the isoforms 
with the second repeat can form extended oligomeric forms mediated by disulfide 
linkages due to the additional cysteines in the second repeat (Figure 3.1 and Figure 3.2). 
Therefore, in this study we utilized tau isoforms containing the second repeat unit to 
study the role of tau aggregation in neurotoxicity. 
Hyperphosphorylation of tau is required for the release of tau from microtubules 
and its mislocalization to the somatodendritic compartment enabling tau to self-associate 
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into oligomers and higher order aggregates. However, the toxicity of tau is not directly 
related to its hyperphosphorylation but rather a mechanism to regulate its interaction with 
tubulin to stabilize microtubules and to regulate transport along microtubules.  
Expression of exogenous tau in mature hippocampal neurons leads to blockage of 
transport along microtubules and degeneration of synapses that can be rescued by 
phosphorylation of tau by kinase MARK2 to unblock the microtubule tracks[16]. 
Significantly, tau in the extracellular space is reported to be less phosphorylated than 
intracellular tau[17-18] and more toxic in its dephosphorylated state[17]. Extracellular 
oligomers of recombinant full-length human tau protein were shown to be neurotoxic in 
mice and impair memory consolidation[19], similar work at other labs has shown a 
similar effects with recombinant tau oligomers and tau oligomers composed of 
hyperphosphorylated tau from AD brain. Thus, the hyperphosphorylation of tau 
associated with disease may be a causal factor in tau self-association into oligomers, but 
the hyperphosphorylation of tau in and of itself may not be the basis for the toxicity of 
extracellular tau oligomers.  
Neurofibrillary tangles (NFTs) have traditionally been correlated with neuronal 
loss[20] and considered to be key intracellular indicators of AD. Approaches for targeting 
tau aggregation have focused on inhibiting hyperphosphorylation and fibril formation, 
reducing total tau levels, or stabilizing microtubules[21]. However, accumulating 
evidence suggests that soluble oligomeric rather than insoluble fibrillar tau species are 
neurotoxic and play an important role in the onset and progression of AD [21-24].  
Although NFTs are a hallmark feature of AD, they can exist in AD neurons for up to 20 
to 30 years[25] before postmortem confirmation and therefore are less likely to induce 
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immediate toxicity in AD brain[26] . In animal models of tauopathy, the presence of 
NFTs does not correlate well with neuronal loss and memory deficits[27]. Reduction in 
neuronal loss and improvement in memory performance are observed despite an increase 
in NFTs[28]. In addition, the presence of NFT pathology does not localize well with 
areas of neuronal loss[29-31], synapse loss or dysfunction in the hippocampus along with 
microglial activation occurs well before the presence of NFTs[32].  In contrast, 
oligomeric tau was implicated in numerous studies as playing a key role in AD 
progression[33-35] and to be a primary initiator of neurotoxicity and 
neurodegeneration[36]. Oligomeric tau has been identified in early stages of neuronal 
cytopathology in AD and closely correlates with hyperphosphorylation on microtubule 
binding sites[24]. Tau oligomers can propagate endogenous tau pathology throughout the 
brain similarly to prions, demonstrating their neuronal toxicity[37]. The presence and 
concentrations of two tau oligomers (140kDa and 170kDa) correlate with memory loss in 
various age rTg4510 mice[33]. Oligomeric tau also induces synaptic and mitochondrial 
dysfunction[19]. Although tau is predominantly intracellular, the role of extracellular tau 
is gaining attention as extracellular oligomeric tau can have acute effects on long-term 
potentiation in hippocampal slices and can transmit pathology to healthy neurons [37]. 
Detection of oligomeric tau levels in human CSF and blood are also promising AD 
diagnostic biomarkers along with total and hyperphosphorylated tau levels[38]. Because 
of the important role of oligomeric tau in AD and the recognition of the importance of 
extracellular tau in disease, it is critical to identify the key toxic tau species in disease 
etiology. Here we studied the extracellular neurotoxicity of monomeric, dimeric and 
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trimeric forms of two four-repeat recombinant human tau variants to help identify the key 
tau species involved in the onset and progression of AD.  
3.3 Material and Methods 
Recombinant human tau (rhTau) preparation and purification- rhTau was purified as 
monomers from bacterial (BL21 DE3) clones with tau constructs in the pET21B and 
pET29a vectors. Standard methods were used to grow and induce the protein with 1 mM 
IPTG. Pelleted cells were lysed with CelLytic B lysis buffer, lysozyme, benzonase, and 
protease inhibitors according to the manufacturer's protocol (Sigma-Aldrich, St. Louis, 
MO)). Cation exchange (GE Healthcare Life Sciences) was used for the first step of 
purification with SP-Sepharose resin for both tau constructs, and 300 mM NaCl in 25 
mM Tris-HCl pH 7.4 was used to elute tau protein. Amicon Ultra Centrifugal Devices 
(Millipore) were used to buffer exchange the protein preparations into 50 mM Tris-HCl 
pH 7.4. Protein concentration was determined using a BCA assay (Thermo Fisher 
Scientific). Tau oligomers were generated by incubating tau monomers at a concentration 
of 5 μM in 50 mM Tris buffer pH 7.4 with 100 mM NaCl at 37 °C overnight. The 
monomeric and oligomeric species were resolved by 6% PAGE, eluted, and buffer 
exchanged into 50 mM Tris-HCl. Fractions were analyzed by non-reducing SDS-PAGE 
to minimize degradation of oligomeric proteins and silver staining to enhance the signal 
and to verify the purity of tau variants. Protein concentration was determined using the 
BCA assay.  
Height distribution analysis- AFM sample preparation and imaging were 
performed as described previously[39-44].  Aliquots of 10 µL 0.50 µM purified tau 
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variants in 50 mM Tris-HCl buffer were deposited on separate mica pieces for imaging 
using MultiMode AFM Nanoscope IIIA system (Veeco/Digital instruments, Santa 
Barbara, CA) which was set in tapping mode and equipped with silicon AFM probes 
(VISTA probes, nanoscience instruments). Height distribution analysis of the different 
tau samples was fit a normal distribution probability model using Gwyddion 2.20. All 
detectable protein molecules were assumed to be spherical and the height values 
approximate their diameters.  
Cell culture and treatments- SH-SY5Y human neuroblastoma cell lines 
(American Tissue Culture Collection) were cultivated in tissue culture flask (Falcon by 
Becton Dickinson Labware). Cells were grown in a medium containing 44% v/v Ham’s 
F-12 (IrvineScientific), 44% v/v MEM Earle’s salts (IrvineScientific), 10% v/v denatured 
fetal bovine serum (FBS) (SigmaAldrich), 1% v/v MEM non-essential amino acids 
(Invitrogen) and 1% v/v antibiotic/antimycotic (Invitrogen). Media were renewed once 
every two to three days. The cells were passaged to a new flask when they were confluent 
in the flask. For toxicity studies, the SH-SY5Y cells were seeded in a 48-well cell culture 
cluster plate (Costar by Corning Incorporated) with 5×104 cells/well in 300ul fresh 
medium. Each experiment was conducted in triplicate. Cell density was estimated by 
reading a fixed volume on a hemocytometer. After growth in a 37°C incubator for 24 
hours, the tissue culture media were replaced with fresh serum-free media for the 
neurotoxicity test on non-differentiated cells. To investigate tau toxicity on cholinergic 
neurons, a duplicate set of the cultured cells was induced into cholinergic-like phenotype 
by incubation with retinoic acid at a final concentration of 10μM for 3 to 5 days[43, 45-
47]. The cultivated non-differentiated and cholinergic-like neurons were treated with 
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monomeric, dimeric and trimeric variants of 1N4R and 2N4R at final concentrations of 
2.26 nM, 4.50 nM, 11.15 nM and 15.50 nM. A PBS negative control was used as a 
standard for subsequent LDH assay analysis. Cultures were incubated with tau species at 
37°C and sampled at 3, 18, 24 and 48 hour time points by harvesting 30 ul/well aliquots 
of culture supernatant.  
LDH assay - The LDH protocol is adapted from a commercial kit (Sigma-Aldrich) 
based on the generic protocol of Decker and Lohmann-Matthes[48]. The LDH assay was 
performed as described previously[40]. Absorbance was measured at 490nm (reference 
wavelength 690nm). Relative absorbance values were calculated by subtracting the 
reference values from the values obtained at 490nm. LDH% values greater than 150 are 
considered toxic. 
Statistical analysis- The relative absorbance value of all samples were normalized 
to that of controls which were set as 100% for each independent experiment. Group mean 
values were analyzed by one-way ANOVA with p<0.05 standard and LSD post hoc 
significant differences test. All analyses were performed with SPSS 21.0 (IBM Corp., 
Armonk, NY). 
3.4 Results  
rhTau aggregate analysis- We expressed recombinant human tau in a bacterial host 
system to eliminate any post-translational phosphorylation of tau and therefore remove 
any potential effects that phosphorylation may have on tau aggregation or loss of function.  
The resulting non-phosphorylated human recombinant tau (NPrhTau) monomers contain 
reactive cysteine groups with free thiols, facilitating the formation of intramolecular 
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disulfide bonds to make stable non-reactive monomers and the formation of 
intermolecular disulfide bonds to produce tau oligomers and higher degree 
aggregates(Figure 3.2). The polymerization reaction is controlled by incubation time and 
protein concentration. The non-reactive monomeric, dimeric and trimeric forms of both 
the 2N4R and 1N4R splice variants generate stable aggregate morphologies with defined 
size profiles dependant on the degree of oligomerization and length of the splice variant 
as evidenced by SDS-PAGE (Figure 3.3) and AFM height distribution analysis (Figure 
3.4).  The oligomer heights increment for each additional monomeric tau unit is fixed 
within a certain isoform, which is 0.5nm for 1N4R variants and 1.0nm for the 2N4R 
variants (Figure 3.4). The size of each respective 2N4R species are also larger than the 
corresponding 1N4R species (Figure 3.3 and Figure 3.4) as expected given that tau 2N4R 
contains the extra N-terminal insert compared with the 1N4R variants.  
Extracellular rhTau induced neurotoxicity test- While neither the monomeric or 
dimeric forms of tau from either the 1N or 2N splice variants displayed detectable 
toxicity, the trimeric form of both variants exerted marked toxicity toward non-
differentiated (Figure 3.5A) and retinoic acid induced cholinergic-like neurons (Figure 
3.5B) with LDH values well above the toxic threshold of 150 at low nanomolar 
concentrations (11.15nM and 15.50nM). The full length 2N4R trimeric tau form 
displayed significantly higher toxicity than the 1N4R trimeric form toward non-
differentiated neurons (Figure 3.5A), although the effect is diminished in the cholinergic-
like neurons (Figure 3.5B).  When trimeric tau was added to non-differentiated SH-SY5Y 
cells, an increase in toxicity was observed with time at the highest concentrations for both 
the 1N4R (Figure 3.6A) and 2N4R (Figure 3.6B) trimeric variants. However when 
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trimeric tau was added to the cholinergic-like neurons, the toxicity of the 1N (Figure 3.6C) 
and 2N (Figure 3.6D) variants was relatively consistent over the first 24 hours, but 
increased after 48 hours. Both variants of trimeric tau showed increased toxicity toward 
the cholinergic-like neurons compared to the non-differentiated neurons at short 
incubation times (Figure 3.7A) but the reverse was observed at longer incubation times 
(Figure 3.7B).   
3.5 Discussion  
While the amyloid cascade hypothesis[49] has dominated studies into the etiology of AD 
over the last decade or more, the importance of tau in the onset and progression of AD is 
steadily becoming more apparent.  Tau pathology has been observed in the absence of Aβ 
deposits in children and young adult cases, and tau aggregates in the entorhinal-
hippocampal regions precedes the onset of Aβ pathology[8-9]. Numerous studies have 
shown that various oligomeric forms of Aβ are toxic to neurons and can impair cognitive 
performance[50-51], thus implicating their potential role as valuable biomarkers for 
diagnosing AD[42, 52-53].   Similar to the important role of various soluble oligomeric 
Aβ species in AD, different soluble oligomeric forms of tau may also play a critical role 
in AD, also causing neuronal loss and cognitive dysfunction[19, 54-55]. Therefore to 
facilitate diagnoses and therapeutic treatments for AD, it is important to identify the key 
tau species involved in the onset and progression of the disease.  Given that tau has 
multiple splice variants and post-translational modification sites, we attempted to 
simplify the complex diversity of tau forms by focusing on two non-phosphorylated 
human recombinant tau isoforms, 1N4R and 2N4R.  These two four-repeat (4R) isoforms 
of tau both have all four repeats of the microtubule-associated domains and are more 
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prone to form the aggregates readily phosphorylated by brain protein kinases than those 
with only three repeats (3R)[56] due to the presence of Repeat 2 with microtubule-
affinity enhancing hexapeptide motifs[14-15] and an additional cysteine that forms 
disulfide linkages to stabilize the aggregates. 
The most disease-relevant tau material to use to study toxicity of extracellular tau 
forms would be well characterized tau oligomers purified from AD cerebrospinal fluid 
(CSF) using methods to preserve their post-translational modifications, including 
phosphorylation, glycation, ubiquitination, aggregation and truncation. Preparations from 
several non-AD and AD cases would be necessary to understand the significance of the 
results. Here we performed an initial study focused specifically on unmodified tau protein 
oligomers and control monomer to specifically understand the relevance of oligomer 
structure to extracellular toxicity.  
We determined the toxicity of the different tau variants using both non-
differentiated and cholinergic-like neuroblastoma cell lines to determine how aggregate 
size and cell phenotype affected toxicity.  Cholinergic cells are particularly vulnerable in 
AD with significant neuronal loss in the nucleus basalis of Meynert (NBM), i.e. the 
hippocampus and the cortex[57]. NBM is enriched in cholinergic cells and undergoes 
degeneration and a significant decrease of acetylcholine production in AD[58]. 
Decreased levels of acetylcholine and a number of other cortical cholinergic markers lead 
to clinical dementia and impairment in cognitive function[58], indicating that cholinergic 
cells are particularly vulnerable in AD. Here we show that trimeric, but not monomeric or 
dimeric tau is toxic to neuronal cells at low nano-molar concentrations, and that the full 
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length 2N tau variant is more toxic than the shorter 1N variant to non-differentiated 
neurons (Figure 3.5). Both trimeric tau variants cause toxicity to both non-differentiated 
SH-SY5Y cells and retinoic acid induced cholinergic-like neurons when tau was applied 
extracellularly at nanomolar levels (Figure 3.6).  However the cultured cholinergic-like 
neurons show increased susceptibility to trimeric tau induced toxicity at short incubation 
times compared with similar non-differentiated neurons (Figure 3.7A), perhaps partially 
accounting for the increased vulnerability of cholinergic-like neurons in AD. Since the 
non-differentiated cells were equally susceptible to trimeric tau induced toxicity at longer 
incubation times (Figure 3.7B), these results suggest that toxicity of extracellular trimeric 
tau is not dependent on receptors or proteins specifically associated with cholinergic cells, 
but that toxicity might be facilitated by them. Our results are consistent with a recent 
study showing that low molecular weight (LMW) misfolded tau species exclusive of 
monomeric tau can be endocytosed by neurons and transported both anterograde and 
retrograde to induce endogenous tau pathology in vivo while fibrillar tau and brain-
derived filamentous tau cannot be endocytosed [59].  This suggests that tau toxicity may 
be spread through cells in certain brain regions by endocytosis of trimeric and larger 
oligomeric forms of tau and that this uptake is facilitated in cholinergic neurons.   
Neuronal toxicity of oligomeric tau may share similar properties to that of 
oligomeric Aβ where the critical feature involved in neuronal toxicity is the aggregation 
state of the protein more than post-translational modifications [23, 60].  While there are a 
wide variety of tau variants that occur in vivo including different post-translational 
modifications, splice variants and aggregated species, this study begins to more 
systematically probe the role of selected tau variants in AD.  Further studies are needed to 
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determine the contribution of splice variants and AD-specific post-translational 
modifications found in extracellular tau to the toxicity of the tau variants and to how 
these tau variants affect other neuronal models including primary neurons or induced 
pluripotent stem cells. Well characterized reagents that can selectively identify specific 
tau variants and morphologies will be useful for these further studies.  
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3.7 Figures and Tables
 
Figure 3.1 Tau protein structural features in linear diagram. A full-length tau protein with 441 amino acids (tau441 
or tau 2N4R) is shown. Alternative splicing showed in yellow rectangles results in total of six isoforms, denoted by 
either their total number of amino acids, or the number of N’ terminal exons (Ns) and microtubule-associated repeats 
(Rs). 
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Figure 3.2 Schematic of non-reactive monomer, reactive monomer and reactive oligomer. Reactivity implies the 
ability to form an intermolecular disulfide linkage. Intramolecular disulfide linkage causes formation of non-reactive 
tau monomer. The free thiols in a reactive monomer allow formation of an intermolecular or intramolecular disulfide 
linkage. Reactive oligomer has one or more free thiols readily forming disulfide linkage with reactive monomeric tau 
for oligomer extension purpose. 
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Figure 3.3 Recombinant human tau (rhTau) monomeric and oligomeric species production and purification. 
rhTau 1N4R enriched with disulfide-mediated tau oligomers (lane 1) was used for the purification of monomeric, 
dimeric and trimeric tau species (lanes 2-4),  rhTau 2N4R purified monomeric, dimeric and trimeric species (lanes 5-7) 
used in these studies. 
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Figure 3.4 Plots of height distribution of monomeric, dimeric and trimeric fractions of rhTau 1N4R (A) and tau 
2N4R (B). The height value of each particle was measured using Gwyddion. The numbers of particles falling in 
continuous size ranges were calculated and normalized into count percentages. The peak values give an approximate 
value for each tau species particle size. As expected, high-degree oligomers are larger than low-degree oligomers 
within the same isoform, and corresponding oligomeric aggregates from the longer isoform are larger than aggregates 
from the shorter isoform. 
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Figure 3.5 Neurotoxicity of extracellular 15.5nM monomeric, dimeric and trimeric forms of 1N4R and 2N4R tau 
variants toward (A) non-differentiated human neuroblastoma cells (SH-SY5Y) and (B) Retinoic-acid-
differentiated SH-SY5Y cells were measured after 48 hour incubation using an LDH assay. For both four-repeat 
tau isoforms, trimeric form is more neurotoxic than monomeric and dimeric forms (P<0.001) on either neuron type. 
Full-length trimeric rhTau is more neurotoxic than 1N4R trimeric rhTau. (P<0.05)  
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Figure 3.6  Time and concentration dependence of neurotoxicity induced by trimeric rhTau (1N4R and 2N4R) 
toward neuroblastoma cells measured by LDH assay. Non-differentiated SH-SY5Y cells incubated with (A) 1N4R 
tau and (B) 2N4R tau; Retinoic-acid-differentiated SH-SY5Y cells incubated with (C) 1N4R tau and (D) 2N4R tau. 
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Figure 3.7  Comparison of rhTau-induced neurotoxicity toward non-differentiated SH-SY5Y cells and Retinoic 
acid (RA)-differentiated SH-SY5Y cells. The data combine toxicity results of 15.5nM monomeric, dimeric and 
trimeric forms of both 1N4R, 2N4R tau variants.  (A) After 3 hours incubation, RA-differentiated SH-SY5Y cells are 
more vulnerable to extracellular trimeric rhTau toxicity than non-differentiated SHSY-5Y cells are (P<0.05). (B)After 
48 hours incubation, non-differentiated SH-SY5Y cells are more vulnerable to extracellular trimeric rhTau toxicity than 
RA-differentiated SH-SY5Y cells (P<0.05).  
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Chapter 4  Isolation and Characterization of Single Chain Variable Fragments Selective for Neurotoxic Tau Oligomers 
4.1 Abstract 
The importance of oligomeric tau in AD has largely been overlooked even though soluble 
aggregates of tau are neurotoxic and can propagate tau tangle pathology to healthy areas 
of the brain. Because of the important role of oligomeric tau in AD onset and progression, 
there is a critical need for well characterized reagents that selectively recognize different 
key morphologies of tau which can be used as tools to study the etiology of AD and 
related diseases.  We developed a biopanning protocol combining the binding diversity of 
phage-displayed antibody libraries with the powerful imaging capability of atomic force 
microscopy (AFM) that enables us to isolate antibody fragments against specific protein 
variants and determine binding specificity using only minimal amounts of target material 
without the need for antigen modification or immobilization.  Here, we show the use of 
this panning technology to generate single chain antibody fragments (scFvs) that 
selectively bind toxic oligomeric tau. We isolated three antibody fragments that each 
selectively bind oligomeric tau but do not cross-react with monomeric or fibrillar tau. 
These scFvs differentially bind hippocampal homogenates of 3×TG-AD mice compared 
to wild type mice and can detect oligomeric tau in these samples at much earlier ages 
than when neurofibrillary tangles are typically detected.  The scFvs also can distinguish 
human post-mortem AD brain tissue from cognitively normal post-mortem human brain 
tissue showing increased reactivity with an increase in Braak stage demonstrating the 
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potential of this approach for developing biomarkers for early detection and progression 
of AD.  
4.2 Introduction 
Alzheimer’s disease (AD) is a devastating progressive neurodegenerative disease that 
causes brain atrophy, memory deterioration and cognitive loss in affected individuals. It 
is the sixth leading cause of death in the United States, currently affecting over 5.4 
million Americans with annual costs of over $200 billion in medical care[1]. Although 
AD was first discovered over a hundred years ago, and substantial progress has been 
made in understanding the etiology of the disease, there are still no effective therapeutic 
or definitive diagnostic approaches available. AD is characterized by the presence of two 
hallmark pathologies: extracellular neuritic plaques containing insoluble fibrillar 
aggregates of amyloid-beta (Aβ) and intracellular neurofibrillary tangles (NFTs) 
containing fibrillar aggregates of tau. Although these insoluble aggregated species have 
long been considered as the primary toxic elements of AD, increasing evidence indicates 
that small soluble oligomeric forms of both Aβ and tau play more critical roles in the 
onset and progression of AD than the fibrillar aggregates[2-4]. The role of 
Aβ aggregation in AD in particular has been extensively studied[5-11], but despite very 
promising results in animal models, various therapeutic routes of targeting Aβ 
aggregation have had only very limited success in clinical trials[12-15].  The role of tau 
in the progression of AD is gaining more attention, including studies to elucidate the 
roles of different variants and aggregate forms of tau[4, 16-23]. 
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Tau is a microtubule-associated protein, generally located in the axons of neurons, 
where it is involved in the assembly and stabilization of microtubules from tubulin. 
Although human tau is encoded by a single gene on chromosome 17q21, six major tau 
isoforms can be formed by alternative posttranscriptional splicing of exons 2, 3 and 10. 
Tau can also be post-translationally modified by phosphorylation, glycosylation, 
ubiquitinylation, or glycation among others[24-26] resulting in a wide variety of different 
tau species that exist in vivo. Since tau hyperphosphorylation is associated with AD, it 
has been extensively studied, and inhibition of kinases involved in tau phosphorylation 
has been pursued as a potential therapeutic approach[27-29]. Levels of phosphorylated 
variants of tau correlate well with AD and other tauopathies including FTD[30]. 
Hyperphosphorylation of the microtubule-binding domain (MBD) of tau results in a 
conformational change that promotes its misfolding and loss of physiological 
function[31]. However, phosphorylation of tau may also be required for some cellular 
functions including adult neurogenesis, as new adult-born granule neurons contain a 
significant amount of a hyperphosphorylated three repeat (3R) tau variants[32]. 
Therapeutic strategies aimed at regulating kinase activity bear the risk of interrupting 
normal phosphorylation dependent functions of tau along with other cellular functions. 
Given the complexity of the many different potential isoforms of tau that can occur in 
vivo and the uncertainty as to the physiological effects of tau hyperphosphorylation and 
aggregation, the roles of different hyperphosphorylated and aggregated tau variants in 
AD remain controversial[19, 29, 33] and the most promising diagnostic or therapeutic 
targets are still not known. 
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Similar to the neurotoxic effects observed with soluble oligomeric aggregates of 
Aβ, numerous studies indicate that soluble aggregates of tau play an important role in the 
pathology of AD[17]. Both brain derived and recombinant oligomeric tau aggregate 
species disrupt intracellular calcium levels and are toxic to cultured human neuronal cells 
when added extracellularly[34-36]. In animal models expressing human tau, 
neurodegeneration-related phenotypes including behavioral impairments, neuronal loss, 
and synapse lesions correlate better with the presence of soluble tau oligomers and pre-
filament species than with fibrillar NFT levels [37-39]. Neuronal loss also precedes NFT 
formation suggesting involvement of other species such as oligomeric tau variants [38, 
40-42]. In postmortem human brains, high oligomeric tau levels were detected in the 
frontal lobe cortex at early stages of AD before the presence of NFTs [43-44]. 
Oligomeric tau may also be responsible for transmission of pathology with a prion-like 
mechanism as NFT tau pathology spreads from brain regions seeded with oligomeric tau 
into other regions resulting in aggregation of endogenous tau[45-48]. We have previously 
shown using recombinant human tau (rhTau) that extracellular trimeric, but not 
monomeric or dimeric species are toxic to human neuronal cells[49].  
Here we describe isolation of antibody based reagents that selectively recognize 
toxic oligomeric tau species. We used an scFv library[50] as a source of binding diversity 
and an AFM based biopanning protocol[51-56] as a selection tool to isolate scFvs that 
selectively bound the trimeric tau species. We utilized several subtractive panning steps 
in the selection protocol to ensure the removal of all scFvs cross-reactive with 
monomeric tau and other off-target proteins. We identified three different scFvs that 
bound trimeric but not monomeric or fibrillar tau. The scFvs react with oligomeric tau in 
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brain tissue from a transgenic AD mouse model that overexpresses both Aβ and 
aggregation prone htau P301L and indicate that significant levels of oligomeric tau are 
present in brain tissue from this mouse model long before NFTs are detected.  The scFvs 
also reacted with oligomeric tau in post-mortem human AD brain tissue.  Levels of 
oligomeric tau in the post-mortem human brain tissue correlate with progression of AD 
as the amount of oligomeric tau detected with the scFvs increases with Braak stage.    
4.3 Material and Methods  
scFv Phage Display Library- The Sheets phage display scFv library[50] with an 
estimated diversity of 6.7×109 was generously provided by Dr. Yu Zhou (Department of 
Anesthesia, University of San Francisco) and used for biopanning. Phage were produced 
and purified as previously described[57]. A final titer of 1013-1014 pfu/mL was used for 
biopanning. 
Aggregated Tau species- Two isoforms (1N4R and 2N4R) of rhTau species were used for 
the panning protocols. Monomeric and oligomeric forms of tau were generated as 
described previously[49]. A fibrillar 2N4R aggregate stock was prepared following a 
heparin fibrillation protocol by mixing rhTau 2N4R monomer (final molarity of 4 µM) 
and low molecular weight heparin (final molarity of 4 µM) in final 20 mM tris-HCl pH 
7.4 and final 5 mM DL-Dithiothreitol (DTT) in deionized water (DI water). The mixture 
was incubated at 37 °C for 2 weeks with occasional stirring.  
Biopanning against rhTau 1N4R trimer- The biopanning process was performed 
essentially as previously described[55] with the following modifications. The biopanning 
process was divided into “subtractive panning” and “positive panning” steps (Figure 4. 1). 
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The subtractive panning steps were designed to remove all scFv-displayed phage from 
the library pool which bound to non-desired antigens. A control protein bovine serum 
albumin (BSA) was used to remove non-specific binding phage, and monomeric tau was 
used to remove all phage binding non-aggregated linear epitopes of tau. The positive 
panning step recovered any scFv-displayed phage from the remaining phage pool that 
selectively bound trimeric tau. Each step was monitored by AFM to ensure that 
essentially all phage binding BSA and monomeric tau were removed and phage binding 
trimeric tau were recovered.   
Subtractive panning step- A set of high affinity immunotubes were coated with 2 
mL/tube of 1 mg/mL BSA in carbonate/bicarbonate coating buffer pH 9.6 and another set 
with 2 mL of 12 µg/mL tau 1N4R monomer in the same coating buffer and incubated 
overnight at 4 ºC. After antigen immobilization, immunotubes were washed extensively 
with phosphate buffered saline (PBS) and sealed to keep moist. A total volume of 0.5 mL 
of the phage display library was added to the first tube coated with BSA. The tube was 
then sealed and incubated at room temperature for 30 minutes with gentle agitation 
ensuring that the phage solution did not contact uncoated regions of the immunotube.  
After incubation, the phage solution was removed and additional unbound phage rinsed 
off with 100 µl PBS. The phage and rinse solutions were combined and added to a second 
tube containing BSA and then to sequential tubes following the same procedure for each 
tube. The final recovered phage solution volume was approximately 1 mL.  A 10 µL 
aliquot of phage solution recovered after incubation with each tube was added to mica 
containing BSA and imaged by AFM to determine whether any phage remaining in the 
phage pool that could still bind BSA. If no bound phage were observed, the subtractive 
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panning step successfully removed essentially all phage binding to the target antigen, in 
this case BSA. A second subtractive panning round was performed using immunotubes 
coated with monomeric 1N4R rhTau to remove all phage binding monomeric tau. The 
process was performed and monitored as described above.  After the second round of 
subtractive panning, the final remaining phage solution was stored in 100 µL aliquots at -
80 ºC. 
Positive panning- A 10 µl aliquot of 60 µg/mL of positive target antigen, trimeric rhTau 
1N4R, was deposited on a piece of freshly cleaved mica, incubated at room temperature 
for 10 minutes, and then extensively washed with DI water and dried. A 200 µl aliquot of 
the remaining phage pool obtained after subtractive panning was added to the mica, 
incubated at room temperature for 10 minutes, and then washed with 2 mL 0.1% 
Tween20/DI water and at least 10 mL DI water to remove all unbound phage. The 
positive panning step was performed in duplicate for analysis by AFM to verify the 
presence of phage binding trimeric tau. Bound phage were eluted with 1.4% 
triethylamine (TEA) and neutralized after 5 minutes with an equal volume of 1M Tris-
HCl pH 7.4 buffer. The eluted phage stock were recovered as described[53]. Single 
colonies were collected, individually grown and stored at -80 ºC.  
Atomic force microscope (AFM) imaging- AFM imaging and analyses were performed as 
described previously[58]. Aliquots were deposited and incubated for 10 min on freshly 
cleaved mica at room temperature before the mica surface was washed extensively with 
DI water and dried with compressed nitrogen flow. To image phage binding specificity 
for the different tau isoforms, an additional stringent wash with 0.1% Tween20/DI water 
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was performed to remove non-specific binding phage. The coated mica samples were 
imaged in air using a MultiMode AFM Nanoscope IIIA system (Veeco/Digital 
instruments, Santa Barbara, CA) operating in tapping mode using silicon AFM probes 
(VISTAprobes, nanoscience instruments).  
Single clone screening with AFM- Following positive panning, a phage preparation from 
each individual recovered clone was analyzed for target binding specificity by AFM. 
Aliquots of each phage were added to mica coated with either BSA, monomeric or 
trimeric tau.  Samples showing the highest binding levels toward trimeric tau, but no 
reactivity toward BSA or monomeric tau were selected for further characterization. 
DNA sequence correction- DNA sequences of recovered clones were obtained and 
compared with other known scFv sequences[57]. All recovered clones from the positive 
panning step contained a missing base pair near the amino terminal of the scFv sequence 
resulting in a shift in the reading frame (Table 4.1). The frameshift was corrected in 
selected clones using polymerase chain reaction (PCR) with customized primers (Table 
4.2). The forward primers encompass the NcoI site (5’-CCATGG-3’) upstream of scFv 
sequence and include the missing base, while the reverse primer encompasses the NotI 
site (5’-GCGGCCGC-3’) downstream of scFv sequence.  The corrected scFv gene 
sequences were ligated into the pGEMT plasmid vector for sequencing to confirm the 
desired DNA sequence, and then ligated into the pIT2 plasmid vector which contains a 
hexahistidine tag and c-myc tag for protein expression.  The pIT2 plasmids were 
transformed into either E. coli strain HB2151 for scFv expression or TG1 for phage 
expression. 
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Phage binding specificity assay- Binding specificities of the sequence corrected phage 
clones were verified by AFM. Purified phage were deposited and incubated on mica 
coated with the different tau species and imaged to confirm binding specificity as 
described above. 
Soluble scFv production and purification- Production and purification of the sequence 
corrected scFv proteins were performed as described previously[51]. Concentrated 
supernatant, periplasm and cell lysate fractions were prepared separately and tested for 
presence of scFv. Most of the scFv was located in the periplasmic fraction, with lower 
amounts excreted to the supernatant as expected[59]. All fractions containing scFv were 
pooled and purified using a Ni-NTA agarose beads column (Qiagen, 5mL beads for 1L 
expression culture) and imidazole elution essentially as described [60]. 
Dot blot assay with human brain tissue- Postmortem human brain samples from the 
middle temporal gyrus (MTG) of Alzheimer’s disease (AD) and cognitively normal non-
demented (ND) cases were generously provided by Dr. Thomas Beach (Director of 
Banner/Sun Health Research Institute Brain Bank). Brain extracts from the MTG of age-
matched ND and AD patients were homogenized in Tris-HCl/EDTA buffer with protease 
inhibitor. The homogenate was spun down to remove solids and the supernatant 
containing all the soluble protein was collected and adjusted to a total protein 
concentration of 3 mg/mL. Aliquots of 2 μL 3 mg/mL brain tissue were dotted on gridded 
nitrocellulose membrane and probed with anti-oligomeric tau scFv essentially as 
described[61]. Samples were analyzed in triplicate using purified scFv.  Reactivity of 
scFv with brain tissue samples was analyzed using ImageJ and recorded in the form of 
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densitometric value[55]. Each value was calibrated on a scale of 0 to 1 in which 0 
denotes the background and 1 denotes the positive control of anti-phosphorylase b (plb) 
scFv.  
Mouse brain tissue- Brains from 5, 8, 11 months old wild-type mice and 5, 9 and 13 
months old 3×transgenic Alzheimer’s (3×TG-AD) mice overexpressing human tau 
P301L[62] were generously provided by Dr. Travis Dunckley (Translational Genomics, 
Phoenix, AZ). Mouse hippocampus was homogenized as described above for human 
brain samples.  
Phage biotinylation- Phage were biotinylated for enhanced signal detection in ELISA 
using the EZ-Link Pentylamine-biotin kit (Thermo Scientific). A 1011 pfu/mL aliquot of 
phage stock (0.729mg/ml) was incubated with Pentylamine-Biotin (4.86mM final 
concentration) and 1-Ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride 
(EDC) of 0.1M final concentration at room temperature for 2 hours with stirring.  Excess 
Pentylamine-Biotin and EDC were removed with desalting columns. 
Capture ELISA- To validate that scFvs were targeting tau and to quantify oligomeric tau 
present in mouse brain samples, we utilized a capture ELISA where high affinity 
polystyrene microtiter 96-well plates were first coated with 100 μl/well of 0.3 mg/ml 
purified scFv (the capture antibody) and incubated at 37 °C for two hours. After the 
unbound scFvs were removed, the plates were washed three times with 0.1% 
Tween20/PBS. The plates were then blocked with 2% non-fat milk/PBS at 37 °C for one 
hour.  After a Tween20/PBS wash, an aliquot of 100 μl/well of 0.2 mg/ml mouse brain 
homogenate (the target analytes) was added, incubated at 37 °C for two hours and then 
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washed with Tween20/PBS. PBS was used as a negative control. A 100 µL/well aliquot 
of 107 pfu/ml biotinylated phage (the detection antibody) was added at 37 °C for two 
hours. The wells were washed with Tween20/PBS, and then a 100 µL/well aliquot of 0.5 
μg/ml avidin-HRP was added and incubated at 37 °C for one hour. The plates were 
washed again with Tween20/PBS and binding monitored using a chemiluminescent 
ELISA kit (SuperSignal ELISA Femto Maximum Sensitivity Substrate (Thermo 
Scientific)). The chemiluminescent signal was read 1 minute after addition to the mixture. 
The immunoreactivity signals were normalized by dividing the absolute 
chemiluminescent readings of the samples by that of PBS control. Within each 
independent experiment, the mean signal obtained from all the wild-type mice samples 
was used as a baseline to normalize the signals obtained with the transgenic mice samples.  
To verify that the isolated scFvs were binding oligomeric tau in the mouse brain 
tissue samples, we utilized a capture ELISA where the scFvs were used as the capture 
antibody and a commercially available anti-tau monoclonal antibody, AT8 (Thermo 
Scientific), was used as the detection antibody. AT8 targets tau forms with 
hyperphosphorylated Ser202/Thr205 mainly found in tau aggregates. An anti-mouse 
antibody conjugated to horseradish peroxidase (HRP) (Thermo Scientific) was used to 
detect bound AT8.   
Size analysis of individual phage target- To determine the size of the target antigen 
bound by individual phage particles, we deposited a 10 µl aliquot of a fibrillar tau 
aggregate mixture (19.5 µg/mL, 10×dilution of the original prepared stock) on mica, 
followed by a 10 µl aliquot of 1012 pfu/ml phage, then incubated and rinsed the sample as 
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described above. The tau aggregate sample contained a mixture of monomeric, 
oligomeric and fibrillar rhTau 2N4R aggregates.  AFM images (5 µm2) were obtained 
and processed using Nanoscope Analysis.  The diameter of each target antigen particle 
bound at the tip of the phage was calculated by taking the difference between the 
maximum height of the particle and the adjusted baseline. At least 6 different antigen 
particles for each individual clone were measured and averaged to determine the particle 
height of the target antigen.   
Statistical analysis- Samples were analyzed by one-way ANOVA with p<0.05 standard 
and LSD post hoc significant differences test. All analyses were performed with SPSS 
21.0 (IBM Corp., Armonk, NY). 
4.4 Results and Discussion  
Isolation of scFvs selectively binding oligomeric tau  
We utilized an AFM based panning protocol incorporating sequential subtractive and 
positive panning steps (Figure 4. 1A) to isolate scFvs that selectively bind a toxic trimeric 
tau species. We first eliminated from the scFv library pool essentially all phage 
containing scFvs binding to the control protein (BSA) (Figure 4. 1B) and then those 
binding to monomeric tau. After the subtractive panning steps, we isolated scFv-
displayed phage that selectively bound toxic oligomeric tau employing a single positive 
panning step using trimeric rhTau 1N4R as the target antigen.  We recovered 96 phage 
clones from the positive panning step against trimeric tau (Figure 4. 1C). Phage from 
each of the 96 clones were prepared separately and each sample was assayed for binding 
specificity to trimeric tau, monomeric tau and BSA by AFM (Figure 4. 2A). We selected 
73 
twenty clones that selectively recognized trimeric tau for further study. The DNA 
sequences were obtained to verify the presence of full length scFv[50, 57], and six 
distinct full-length scFvs were selected for further analysis (H2, F9, D11, H7, D4 and 
G12).  Although all six clones contained complete scFv sequences, they each lacked a 
DNA base pair downstream of the N-terminal NcoI site and the methionine start codon 
(Table 4.1) resulting in a reading frame shift. The pelB leader sequence contains multiple 
methionine start codons in different reading frames that may facilitate the expression of 
full length scFvs despite the altered reading frame resulting from the missing base pair at 
the N-terminal. To enhance soluble scFvs expression efficiency, we corrected the reading 
frame shift using PCR. We then verified that the each sequence corrected scFv 
maintained the same binding specificity of the original clone using AFM (Figure 4. 2B). 
Three sequence corrected clones F9T, D11C and H2A were then selected for further 
studies based on binding specificity and distinctive CDR sequences. 
Verification of binding specificity to tau trimer 
To verify that the F9T, D11C and H2A scFvs were selectively binding trimeric 
tau, we incubated a phage displayed version of each scFv with a sample of aggregated tau 
and used AFM to determine the average height of the particles bound by each phage 
particle. We then compared the height of the bound particles to the known height values 
of different tau aggregate species[49]. A representative AFM image of an F9T scFv 
phage (blue arrow) binding to a target rhTau 2N4R aggregate (gray arrow) in the mixed 
monomeric, oligomeric and fibrillar (black arrow) tau sample is shown (Figure 4. 3A).   
The average height of at least 6 different bound antigens for each scFv was determined 
and compared to the size of known oligomeric tau aggregates[49].  The target antigen 
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size for all three scFvs correspond to the size of a rhTau 2N4R trimer[49] (from 2.5 nm to 
3.0 nm) providing further evidence that the scFvs selectively target trimeric tau (Figure 4. 
3B).  
Characterization of binding epitopes  
Purified soluble scFv protein for each corrected scFv sequence had the expected 29 kDa 
full length scFv molecular mass (Figure 4. 2C). Since the scFvs were isolated against a 
synthetic oligomeric tau variant, we then tested whether the purified F9T, D11C and H2A 
scFvs could recognize tau aggregates from brain tissue of an AD mouse model and 
whether they cross-react with other proteins present in brain specimens. All three scFv 
clones bound oligomeric tau aggregates present in hippocampal tissue homogenates from 
9-month old 3×TG-AD mice and none of them showed significant reactivity with wild-
type mice (Figure 4. 4). AT8 was used as a detection antibody to verify that the scFvs can 
also bind tau oligomers that are modified by hyperphosphorylation.  
Since the three selected clones (F9T, D11C and H2A) contain distinctive CDR 
sequences, we tested whether they bind similar or different epitopes on the tau oligomers. 
A capture ELISA method was performed using the purified scFvs as capture antibodies 
and the phage displayed version of each scFv as detection antibodies (Figure 4. 5) with 
the 3×TG-AD mouse brain homogenates as antigen.  When F9T-displayed phage was 
used as the detection antibody, strong signals were obtained for all three capture antibody 
types.   In contrast, when D11C-displayed phage was used as a detection antibody, lower 
signals were obtained with either D11C or H2A scFv as capture antibody, and no signal 
with F9T scFv as capture antibody. Similarly, when H2A-displayed phage was used as a 
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detection antibody, a lower signal was obtained with D11C scFv as the capture antibody 
and no signal with either F9T or H2A scFv as capture antibody (Figure 4. 5).  Since F9T 
phage produced the strongest immunoreactivity with brain extracts retained by all three 
scFvs as capture antibody, we used F9T phage as the detection antibody in all further 
capture ELISAs.  
Time dependent tau oligomer accumulation in AD mouse hippocampus 
We analyzed how oligomeric tau levels varied with time in the hippocampus of 
3×TG-AD mice[63] using the three scFvs against oligomeric tau.  The 3×TG-AD mouse 
model overexpresses human mutant tauP301L (0N4R), which is prone to aggregation in 
tauopathies[64-66]. Whereas insoluble tau tangles are typically detected around 12-15 
months of age in this mouse model[62], oligomeric tau levels are already quite high at 5-
months of age, peak around 9-months and are declining by 13-months (Figure 4. 6). 
Samples from age-matched wild-type mice did not contain any oligomeric tau reactive 
with these scFvs (Figure 4. 6).  Since the scFvs were isolated against 1N4R trimeric tau, 
but also recognize 2N4R (Figure 4. 3) and 0N4R (Figure 4. 4) oligomeric tau aggregates, 
but not monomeric or fibrillar tau aggregates, the scFvs target a common conformational 
feature of the oligomeric tau aggregates and not an isoform specific epitope. Since the 
concentration of oligomeric tau species increases at early time points (5-9 months) before 
insoluble tau tangles begin to form, and then decreases after neurofibrillary tangles begin 
to form (12-15 months), it may be the oligomeric tau species are being incorporated into 
the NFTs. Since oligomeric tau aggregates are already present at 5-months well before 
presence of NFTs, these aggregates have promise as an early diagnostic for AD. 
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Analysis of post-mortem human brain tissue 
Since the scFvs effectively detected oligomeric tau species present in brain tissue from an 
AD mouse model, we next probed post-mortem extracts of human middle temporal gyrus 
(MTG) specimens at different Braak stages for the presence of oligomeric tau using the 
F9T scFv using dot blots (Figure 4. 7).  In postmortem examination on severe AD brains 
and ND brains, middle temporal lobe display conspicuous atrophy and weight loss in AD 
brains[67]. When probed with the anti-oligomeric tau scFvs we could detect only 
minimal oligomeric tau in the ND Braak stage I-II samples, higher values in the ND 
Braak stage I-II samples with slight plaques, higher values again in AD samples with 
moderate plaques (Braak stage III-IV) and the highest signals in AD samples with heavy 
plaques (Braak stage V-VI). There were significantly higher levels of oligomeric tau in 
the AD samples compared to both the ND samples without plaques and the ND samples 
with slight plaques.  While NFTs are typically not detected in MTG until Braak stage 
IV[68-70] we can detect the presence of oligomeric tau aggregates in Braak stage I-II 
samples that also contain a slight amyloid plaque load again suggesting that the presence 
of oligomeric tau may be a promising early biomarker for AD.   
4.5 Summary 
Aggregates of Aβ and tau are the primary protein constituents of the hallmark senile 
plaques and neurofibrillary tangles of AD[71-73], respectively. While many studies have 
focused on accumulation and aggregation of Aβ as an initiating factor in AD 
pathogenesis and neuronal death with tau dysfunction considered to be a downstream 
event following Aβ aggregation[74-75], other studies suggest that tau interacts with Aβ to 
accelerate the progression of AD, and that reducing aggregated tau levels is also 
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important to ameliorate AD symptoms[76]. Aβ and tau aggregation may be linked by 
separate mechanisms driven by common upstream causes[77]. Numerous studies have 
implicated the role of soluble oligomeric Aβ species in mediating toxicity in AD[78-80], 
and evidence now suggests that oligomeric tau may also play toxic roles in AD[17, 44, 
81-82]. Recent studies indicate that soluble tau species including oligomeric, prefibrillar 
and immature pre-filament forms play more crucial roles in AD than the hallmark NFTs 
which instead may rather play an adaptive and protective role[33, 81].  Oligomeric tau 
has been shown to have prion-like self-propagating features[48] and can be taken up by 
endocytosis into neurons where they can induce endogenous tau pathology in vivo[83]. 
Therefore the roles of oligomeric and fibrillar tau species in AD progression is drawing 
increased attention and oligomeric tau is a promising therapeutic target for AD[33, 84-
85]. Because of the diversity of tau species that may be present in the human brain due to 
the alternative post-transcriptional splicing and post-translational modifications that may 
occur, there is a critical need to develop reagents that can selectively identify individual 
tau aggregate variants to probe the roles of the various forms in disease progression and 
to assess their value as diagnostic and therapeutic targets.  
We previously reported that a trimeric, but not monomeric or dimeric tau species 
was neurotoxic at low nanomolar levels[49]. Here we isolated three different scFvs (F9T, 
D11C and H2A) that selectively recognize this toxic trimeric tau species. All three scFvs 
can detect the presence of oligomeric tau species in an AD mouse model by 5-months of 
age well before the presence of NFTs.  The scFvs can also detect oligomeric tau 
aggregates in post-mortem human AD brain tissue samples, where levels of oligomeric 
tau correspond to Braak stage, a classification based on Aβ plaque and abnormal tau 
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immunohistochemical staining[68-70, 86-89].  . While NFTs are a hallmark feature of 
AD, oligomeric tau species may play an intermediate role in tau aggregation[44] and 
have been shown to play an important role in neuronal toxicity. Here we show that 
oligomeric tau aggregates can be detected much earlier than NFTs in mouse models of 
AD and levels of these aggregates correlate with progression of AD in human post-
mortem tissue.  Therefore detection of toxic oligomeric tau aggregates has promise not 
only as an early diagnostic for AD but also to help stage progression of the disease. 
4.6 Acknowledgements 
We appreciate the support from Arizona Department of Health Services for the Arizona 
Department of Health Services for the Arizona Alzheimer’s Consortium. We are grateful 
to the Banner/Sun Health Research Institute Brain Donation Program of Sun City, 
Arizona for the provision of human brain tissue.  The Brain Donation Program is 
supported by the National Institute on Aging (P30 AG19610 Arizona Alzheimer’s 
Disease Core Center), the Arizona Department of Health Services (contract 211002, 
Arizona Alzheimer’s Research Center), the Arizona Biomedical Research Commission 
(contracts 4001, 0011, 05-901 and 1001 to the Arizona Parkinson's Disease Consortium) 
and the Prescott Family Initiative of the Michael J. Fox Foundation for Parkinson’s 
Research.  We would also give thanks to Dr. Debra Page Baluch in the ASU Keck’s 
bioimaging laboratory for the access to AFM facilities and Dr. Travis Dunckley from 
TGen for providing 3×TG-AD mice brains. This work was partially supported by the 
NIH; NIA grant # AG029777. 
  
79 
Appendix 
Conflict of Interest 
Eliot Davidowitz, Patricia Lopez, and James Moe are employees of Oligomerix Inc.,3960 
Broadway, New York, NY 10032 USA.  Partial funding for this work was provided by 
Oligomerix, Inc.  There are no other conflicts of interest.  
 
Abbreviations used 
Aβ, amyloid beta; AD, Alzheimer's disease; AFM, atomic force microscopy; ANOVA, 
analysis of variance; BSA, bovine serum albumin; CDR, complementarity-determining 
region; DI water, deionized water; DTT, DL-Dithiothreitol; EDC, 1-Ethyl-3-[3-
dimethylaminopropyl] carbodiimide hydrochloride; EDTA, Ethylenediaminetetraacetic 
acid; ELISA, enzyme-linked immunosorbent assay; FTD, frontotemporal dementia; 
HCFR, heavy chain framework region; HRP, horseradish peroxidase; LSD, lease 
significant difference; MBD, microtubule-binding domain; MTG, middle temporal gyrus;  
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4.7 Figures and Tables 
 
Figure 4. 1 The novel biopanning process combines subtractive panning and positive panning from phagemid 
scFv library and the single cloning screening using AFM. (A)Schematic of the AFM based panning process. (B) 
Subtractive panning against BSA after 1 (left), 3 (middle) and 5 (right) rounds of negative panning.  The absence of 
phage after 5 rounds of negative panning indicated that the BSA subtractive panning step was complete. The scale bar 
of 1 µm applies to all three images. (C) Positive panning against tau trimer was performed and imaged with AFM. Left 
image: purified trimeric tau 1N4R immobilized on mica; Right image: same sample after addition of the remaining 
phage pool from subtractive panning and rinse, and it shows phage bound to target antigen. The scale bar of 1 µm 
applies to both images. 
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Figure 4. 2 Single clones against trimeric rhTau selection, expression and purification. (A) Representative AFM 
images of single clone selection based on the specificity to trimeric tau (right) against monomeric (left) and BSA. The 
scale bar of 1 µm applies to both images.  (B) Representative AFM images of sequence corrected phage displayed scFv 
(F9T) incubated with tau 2N4R monomer (left) and trimer (right). The scale bar of 1 µm applies to both images.  (C) 
SDS-PAGE of F9T scFv periplasmic preparation shows full length 29 kDa protein.  Lane 1, wash after scFv loading; 
lane 2 to lane 4, elution with imidazole of 200 mM, 100 mM and 50 mM; lane 5, periplasm flow through nickel beads 
column; lane 6, molecular weight standards.  
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Figure 4. 3 Particle size analysis of oligomeric tau bound to scFv-displayed phage from rhTau 2N4R mixed 
aggregates. (A) Representative AFM image of F9T phage (blue arrow) interacting with rhTau 2N4R mixed aggregates 
containing oligomers (gray arrow) and fibrils (black arrow). (B) Size of purified rhTau monomer, dimer and trimer 
compared to average size of antigens bound by F9T, D11C and H2A phage. The size of each individual particle bound 
at the tip of a phage particle was measured using the section function in Nanoscope Analysis. The mean value of the 
particles targeted by each phage is between 2.5 nm and 3.0 nm, consistent with the size of trimeric rhTau 2N4R (Error 
bar:+/- standard deviation).  
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Figure 4. 4 Selective reactivity of F9T, D11C and H2A scFvs with 9-month 3×TG-AD mouse brain tissue.  F9T, 
D11C or H2A scFv were used as capture antibody. Mouse hippocampus homogenates from 3×TG-AD mice and wild-
type mice were added as target analytes. PBS was used as the negative control. The bound tau aggregates were detected 
using anti-tau antibody AT8 conjugated with HRP. Relative immunoreactivities are chemiluminescent signal ratio to 
the mean value of PBS negative controls.  (Error bar:+/- standard deviation) 
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Figure 4. 5  Capture ELISA for detection of oligomeric tau.  Each scFv was utilized as a capture antibody in 
combination with each phage displayed scFv as the detection antibody using 9-month 3×TG-AD mice brain 
homogenates as antigen.  All three scFvs produced the strongest signal when F9T phage was used as detection antibody. 
The mean comparison was performed within each group of the same capture antibody. Relative immunoreactivities are 
chemiluminescent signal ratio to the mean value of wild type mice. (Error bar:+/- standard deviation) 
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Figure 4. 6 Oligomeric tau levels in different age 3×TG-AD mice brain extracts.  The levels of oligomeric tau in 
the different age 3×TG-AD and wild-type mice were determined using the F9T, D11C and H2A scFvs as the capture 
antibody and F9T scFv displayed phage as the detection antibody.  Two mice for each age group were tested in 
triplicate. The data were grouped by the age of the mice. The mean comparison was performed within each age 
matched group. Oligomeric tau levels peak at 9 months and decrease by 13 months. Relative immunoreactivities are 
chemiluminescent signal ratio to the mean value of wild type mice (Error bar:+/- standard deviation).  
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Figure 4. 7 Oligomeric tau levels in post-mortem human brain samples as a function of Braak stage.  Brain 
homogenates from age-matched human middle temporal gyrus (MTG) were blotted on membranes and probed for 
presence of oligomeric tau using F9T scFv. Signals were scaled between 0 and 1 by ImageJ analysis where 0 is the 
background signal and 1 is the positive control signal. Statistical analysis was performed in one-way ANOVA 
comparing means of two groups. (A) non-demented (ND) and Alzheimer’s (AD) and (B) Braak stages and neuritic 
plaque frequencies. Braak stages I-II slight or no plaques; Braak stages III-IV moderate plaques; Braak stages V-VI 
severe plaques. Oligomeric tau levels as determined by reactivity with F9T correlates directly with Braak stages and 
plaque frequency with increasing oligomeric tau levels with increasing Braak stage. (C) Sample dot blot affinity assay 
of homogenized MTG tissue from human non-demented and AD tissue probed with F9T scFv.  
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Table 4. 1 DNA sequences of the N-terminal region and the first heavy chain framework region (HCFR1) of 
recovered scFvs after panning compared to known scFvs. F9, H7, D4, D11 and G12 were recovered from the 
panning protocol, others are published scFv sequences. All recovered scFvs contain similar framework regions as 
published sequences except for a missing nucleotide near the N-terminal.  
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Table 4.2 Designed primers for correction of missing base pair. Forward primers contain the NcoI (5’-CCATGG-3’ 
in italic) site upstream of scFv sequence and the missing base pair (underlined). The reverse primer includes the NotI 
(5’-GCGGCCGC-3’ in italic) site downstream of scFv sequence.   
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Chapter 5 The role of tau oligomer in traumatic brain injury progression in rodent models 
5.1 Abstract 
In Alzheimer’s disease (AD), tau undergoes oligomerization as well as phosphorylation 
during its transforming from normal monomeric microtubule-associate protein to the 
main constituent of neurofibrillary tangles (NFTs). Although phosphorylation has been 
long considered key pathological feature of AD tau, soluble oligomeric tau species may 
play a more critical role in AD progression as we previously demonstrated that human 
recombinant tau oligomers are extracellularly toxic to neuroblastoma cells and that non-
phosphorylated oligomeric tau was detected AD tau transgenic mouse brain at early stage. 
We have developed a novel biopanning technique based on AFM to obtain two groups of 
single chain variable fragments (scFv) targeting toxic tau oligomeric forms and general 
small molecule tau species respectively. The scFvs recognizing generally all small 
soluble tau monomer and/or oligomers particularly non-phosphorylated types make a tau 
antibody detecting or confirming such tau species different from phosphorylated tau 
conventional tau antibodies do. Combined with these novel tau detecting antibodies, the 
group of scFvs targeting oligomeric tau makes a useful tool of better understanding the 
tau aggregating and tau oligomer’s role in AD progressions. 
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5.2 Introduction 
Alzheimer’s disease (AD) is the most common age-related neurodegenerative disease, of 
which the main symptoms are loss of brain functions like memory and cognition, brain 
atrophy and neuron death[1-2]. Tau protein in monomeric form is an important 
microtubule associated protein in human neurons. However in AD, tau was found in 
hyperphosphorylated and highly aggregated insoluble form, as the main component of 
neurofibrillary tangles (NFTs) which is one of the two AD pathological features. 
Phosphorylation had been the main research focus of tau’s effects on AD and potential 
therapeutic approaches for many years[3-5], since all tau found in NFTs are 
hyperphosphorylated, markedly different from normal tau phosphorylation level and sites. 
Also, these phosphorylation sites found in tangled tau are more related to its assembly 
domain crucial for interaction with microtubule, thus the phosphorylation is considered 
interrupt tau’s normal function. However, oligomeric tau has been recently taking up the 
share of high attention from tau phosphorylation as a valuable target for studying AD 
pathogenesis and treating AD, despite the fact that it is not directly discovered in 
postmortem AD brains. Tau oligomers demonstrate close correlation with 
neurodegenerative-associated phenotypes such as synapse lesion, neuronal death and 
behavioral impairment in human tau expressing animal models[6-8]. In postmortem 
frontal lobe cortex of early AD patients, oligomeric tau species were detected before 
NFTs’ presence[9-10]. Tau oligomers are also detected in middle temporal gyrus of AD 
patients at different Braak stages with the tau oligomer concentration increasing 
corresponding to AD progression and preceding the presence and increasing the plaque 
and tangles, as indicated in Chapter 4.  Oligomeric tau was implied in other studies to 
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follow a prion-like mechanism to transmit AD pathologies, similar as but preceding NFT 
tau pathology spreading from brain regions seeded with oligomeric tau into other regions 
resulting in aggregation of endogenous tau[11-14]. These discoveries point out that 
neuronal toxicity and loss precede the formation of NFTs, which suggests a precursor of 
NFTs’ existence, mostly likely tau oligomers is an early indicator of AD and possible 
cause for AD pathogenesis and development[7, 15-16].  
In our study, we develop two groups of scFvs targeting toxic oligomeric tau and 
general small molecular tau including tau monomers and oligomers. The former group of 
scFvs is a potential powerful tool to detect abnormal tau oligomers in trace amount 
existing in brain tissues from human AD patients and triple transgenic AD-like mice as 
described in Chapter 4. These later group of scFvs in forms of scFv-displayed phage were 
tested and confirmed to recognize any small non-aggregated tau species including 
monomer, dimer, trimer and small oligomers regardless of their phosphorylation 
conditions, which make them better small tau detectors in our study than commercial 
phosphorylated tau detecting antibody.  
In addition to AD, tau pathology is present in other neurodegenerative diseases. 
For instance, tau lesions are found as a major feature in repetitive closed head injury 
including chronic traumatic encephalopathy (CTE)[17] that commonly afflicts 
professional contact sports athletes such as football players[18] and boxers[19-20]. A 
recent study using an aged mouse model expressing human tau suggests that repetitive 
mild traumatic brain injury can augment tau pathology and glial activation based on the 
presence of hyperphosphorylated or aggregated tau in mouse brain sections[21]. Since we 
100 
can selectively detect the presence of oligomeric tau, we would like to determine if 
oligomeric tau is an early marker of brain injury using rodent models that undergo single 
or repetitive traumatic brain injury. In this chapter, we test F9T’s ability of distinguishing 
human mutant tau (htau406) knock-in mice and traumatic brain injury (TBI) rodent 
models by recognizing abnormal tau in their hippocampus sections and brain 
homogenates, with a novel high sensitivity capture ELISA and immunohistochemical 
(IHC) staining techniques, respectively. According to the results, we propose that F9T 
has the potential of recognizing abnormal tau intermediate forms in brain section and 
thusly diagnosing tau induced brain damage at its early stage. 
5.3 Material and Methods 
Biopanning against small molecule tau- During the single clone screening process of 
biopanning against trimeric tau described in Chapter 4, we discovered scFv-displayed 
phage clones that recognized monomeric tau species as well as trimeric tau from 
irrelevant antigens such as BSA. Another separate biopanning against monomeric tau 
using Tomlinson I and J library was also performed to obtain scFv specific to small 
molecule tau including monomeric tau and low MW oligomeric tau. These scFvs were 
also confirmed specificity using monoclonal ELISA described as previously[22]. All 
clones from Sheets library that contain a frameshift in the first framework region in heavy 
chain region have been fixed following the same procedures as described in Chapter 4 
and confirmed  it maintained its specificity. 
Cell culture and lysis- SH-SY5Y-TMHT441 cells was designed and provided by Dr. 
Birgit Hutter-Paier group in QPS, Austria. The cells was transfected with stable mutant 
101 
human tau enabling this cell line express tau phosphorylated at AD-related sites[23]. It 
was cultivated using a revised protocol based on that of cultivating SHSY-5Y human 
neuroblastoma cell lines (American Tissue Culture Collection)[24]. The culture medium 
contains 44% v/v Ham’s F-12 (IrvineScientific), 44% v/v MEM Earle’s salts 
(IrvineScientific), 10% v/v denatured fetal bovine serum (FBS) (SigmaAldrich), 1% v/v 
MEM non-essential amino acids (Invitrogen) , 1% v/v antibiotic/antimycotic (Invitrogen), 
and additional 300 μg/mL Geneticin G-418 for first few reviving passages, compared 
with culturing SH-SY5Y cells. Both SH-SY5Y and SH-SY5Y-TMHT441 were cultured 
in multiple 250mL Falcon sterile tissue culture flasks with vented caps. After the cell 
cultures grew confluent in the flask, the media were collected and centrifuge to collect 
the cell culture supernatant. The cells were also scraped off the flasks and washed twice 
with PBS. NP40 cell lysis buffer (invitrogen) freshly mixed with 1/10 volume of protease 
inhibitor cocktail (Sigma Cat.#P-2714) were added to cell pellet at the ratio of 108 
cells/mL buffer to resuspend for lysis. The cell and lysis buffer mixture were ice 
incubated for 30 min with vortexing at 10 min intervals, then centrifuged at 13,000 rpm 
for 10 min at 4°C to collect supernatant as neuronal lysate, which should be store as 
aliquots in -80 °C. 
Tau406+/TauKO mouse model- It is a genetically modified mouse model base on mouse 
tau knock out model. The experiment group is mutant human tau (4R) transgenic mouse 
(Tau406+/TauKO), while the negative control group is without mutant human tau knock-
in(Tau406-/TauKO). This humanized transgenic mouse model is provided by Dr. Paul 
Fraser (Cleveland Clinic, Cleveland, OH).  Human cortex and hippocampus from tau-
associated dementia patients and non-demented controls are provided by Banner/Sun 
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Health Research Institute. The brain tissue homogenization follows the same protocol 
described in Chapter 4. 
Traumatic brain injury (TBI) mouse model- The TBI mouse models and the control mice 
treated with corresponding times of anesthesia were generously provided by Dr. Fiona 
Crawford from Roskamp Institute, Sarasota, FL. All these mouse models were 
constructed from wild type (C57BL6) mice. The TBI mouse were injured at the age of 8-
10 weeks and euthanatized 6 months post-injury, therefore the brains were essentially 8 
to 8.5 months old. This time point was selected because we saw evidence for tau 
phosphorylation (CP13) in injured mice at this time point. The TBI mice have undergone 
either single mild injury (s-mTBI) or repetitive injury (r-mTBI), while the control mice 
(s-sham and r-sham) were treated at the same time points as TBI mouse with isoflurane 
alternated with oxygen as described previously[21]. The brain sections were provided 
from two mice per group and kept anonymous until the IHC staining result comes out. 
Traumatic brain injury (TBI) rat model- The TBI rats model were created and provided 
by Dr. Sarah Stabenfeldt, Arizona State University. TBI rats were sacrificed 7 days or 14 
days after head concussive treatment, with wild type TBI treated with anesthesia as 
negative control (sham). Selected brain sections (I-cortex, I-hippocampus, cerebel) of 
these two different rat age groups and control rats were homogenized shortly after 
sacrifice, and only the homogenates were provided for potential abnormal tau detection. 
High sensitivity capture ELISA- We developed a high sensitivity capture ELISA based on 
the capture ELISA protocol described in Chapter 3, to evaluate scFvs’ ability of detecting 
trace amount of oligomer tau in neuronal lysate, brain homogenate, CSF or serum 
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samples. scFv was produced using in scFv encoded E.coli culture at the early exponential 
phage (OD600=0.3) with IPTG expressing soluble scFv at room temperature overnight. 
The expression culture was centrifuged and the supernatant containing active scFv was 
added 0.1% Tween20 and used as the capture antibody to coat the high affinity 
polystyrene microtiter 96-well plates. The plates were incubated at 50rpm slow shaking 
37 °C for one hour for thorough coating before the unbound scFvs were removed. The 
plates were then washed three times with 0.1% Tween20/PBS and blocked with 2% non-
fat milk/PBS at 50rpm slow shaking 37 °C for one hour. After repeating the 
Tween20/PBS wash, an aliquot of 100 μl/well of 2.5 µg/ml target analyte (brain 
homogenate, neuroblastoma lysate, serum etc.) was added, incubated at 50rpm slow 
shaking 37 °C for one hour and then washed with Tween20/PBS. PBS replaces target 
analytes to act as a negative control. A 100 µL/well aliquot of 0.35mg/ml monomeric tau 
targeting phage (the detection antibody) was added and incubated at 37 °C slow shaking 
for one hour. The wells were washed four times with Tween20/PBS for thorough removal 
of detecting phage. The remaining bound phage were then detected by 100 µL/well 
aliquots of 1:2000 dilution anti-M13 conjugated with HRP (GE) by incubation at 37 °C 
slow shaking for one hour. After four times wash with Tween20/PBS, the plates binding 
condintion were monitored using a chemiluminescent ELISA kit (SuperSignal ELISA 
Femto Maximum Sensitivity Substrate (Thermo Scientific)). The chemiluminescent 
signal peaks at 1 minute after the addition of the substrate mixture and was recorded then. 
The immunoreactivity signals were normalized by dividing the absolute 
chemiluminescent readings of the samples by that of PBS control within each 
independent experiment.  
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Immunohistochemical (IHC) staining- TBI and wild-type mouse brains were sectioned 
and immunohistochemcial stained following IHC-paraffin protocol. F9T scFv was used 
as the primary antibody to incubate with brain sections in 4°C overnight. After thorough 
rinse 3 times for 5 minutes each with TBS + 0.025 % Triton × 100, the remaining scFv 
due to the specific binding was detected with 9E10 mouse anti-cmyc antibody, goat anti-
mouse antibody conjugated with HRP, which reacts with the substrate DAB, in order to 
visualize it chromogenically. 
5.4 Results and discussion 
ScFv selection against small molecule tau- We performed high sensitivity capture ELISA 
to select the most specific and sensitive scFv against small molecule tau (i.e. monomeric 
and low MW oligomeric tau) from the pool of scFvs obtained from biopanning, by using 
them as the detection antibody and comparing their sensitivity. We used F9T scFv as 
capture antibody, because this scFv previously proved its ability to capture abnormal tau 
species from tau transgenic mice brain homogenates.  We used SHSY5Y-TMHT441 cell 
lysate and supernatant as two of the target analytes as it contains human tau aggregates 
detectable by AT8 and F9T(Figure 5.1). SHSY5Y cell lysate and supernatant were used 
as negative analytes, while PBS was used as negative control and background. Among all 
scFvs targeting small molecular tau, F3A, 3B5, 4H3 and WX5 display strong reaction 
with tau species captured by F9T in SHSY5Y-TMHT441 lysate, which was confirmed by 
detecting 10 times dilution of the lysate returning a significant lower signal (Figure 5.2). 
These four clones were further confirmed valid detecting antibody when they were used 
to comparing the pathological oligomeric tau contents in SHSY5Y-TMHT441 and wild 
type SHSY5Y lysates and supernatant.  As the results show, SHSY5Y-TMHT441 lysate 
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(protein concentration 0.137mg/ml) contains large amount small tau oligomers that can 
be captured by F9T and recognized by scFv targeting all small tau molecules regardless 
of its phosphorylation condition, while SHSY5Y-TMHT441 supernatant doesn’t despite 
its high protein contents(1.426mg/ml or 3.215mg/ml) (Figure 5.3). Wild type SHSY5Y 
doesn’t contain such tau oligomers either in lysate (0.137mg/ml) or supernatant 
(1.426mg/ml) when tested at the equal corresponding protein concentration (Figure 5.3). 
All four selected clones display the ability of distinguish SHSY5Y-TMHT441 lysate 
from other three types of analytes, and thus were used in our tests of the existence of 
abnormal tau oligomers in human tau transgenic mice brain homogenates. 
Detection of tau oligomers in mutant human tau transgenic mouse model- In high 
sensitivity capture ELISA, F9T scFv captured all available tau oligomers it recognized in 
mutant human tau transgenic mice (Tau406+/TauKO mouse) brain homogenates, 
therefore the amount of tau oligomers later detectable by F3A scFv-displayed phage 
reflects the tau oligomers concentration in the brain of this particular mouse. As shown in 
Figure 5.4, Tau406+/TauKO mouse group of 3-month age displays no significant 
different signal from its Tau406-/TauKO control mouse group. However, 
Tau406+/TauKO mouse group of 6-month age shows a significantly higher signal than 
Tau406-/TauKO control mouse group (p<0.05), indicating a positive result for oligomeric 
tau presence in the Tau406+/TauKO mice. This implies that between 3 months and 6 
months of Tau406+/TauKO mice, human mutant tau related oligomerization starts to take 
place and gets ready to form into other types of pathological tau detectable by F9T and 
F3A. 
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Detection of abnormal tau species in TBI rodent models- We performed 
immunohistochemical staining on hippocampus sections from TBI mice and have shown 
that oligomeric tau is selectively present in single and repetitive mild TBI mouse 
hippocampus sections (Figure 5.5) suggesting that oligomeric tau is a promising 
biomarker for patients suffering from TBI and CTE. We further analyzed F9T’s affinity 
to another TBI rat model determine the time course profile and the various brain parts 
profile of oligomeric tau following traumatic brain injury. We performed high sensitivity 
capture ELISA of oligomeric tau targeting scFv capturing potential target in TBI rats’ 
brain homogenates detected by small tau targeting scFv-displayed phage clones. In the 
test group of F9T scFv as capture antibody and 3B5 phage as detecting antibody, all three 
brain sections of 7 day after TBI treatment displays a distinct increase in oligomeric tau 
concentration compared with corresponding section from sham negative control. On the 
contrary, rats sacrificed 14 day after TBI treatment contains lower oligomeric tau 
concentration than sham negative control rats in all three corresponding brain 
sections(Figure 5.6). This trend suggests a process of tau oligomer appearing and 
aggregating into other forms undetectable by F9T. 
5.5 Summary  
Tau has been studied as a key factor to AD pathogenesis, for the presence of its 
hyperphosphorylated aggregated form found in neurofibrillary tangles (NFTs). The 
research are mainly focused on hyperphosphorylation until recently discoveries point out 
that tau oligomer are more responsible for neuronal toxicity and tau pathology spreading 
onto healthy brain sections. Clearance of NFTs can't alleviate the AD progress or reduce 
neuronal loss. Therefore, a reagent targeting tau oligomers or general small molecules 
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regardless of its phosphorylation degree is a promising tool for scientists to better 
understanding of tau oligomeric structure’s role in neurotoxicity and AD progression. We 
previous identified trimeric recombinant human tau (rhTau) is the most extracellular 
toxic to neuroblastom cells SHSY5Y and to its cholinergic-like differentiated form, 
comparing with monomeric and dimeric rhTau[24]. Therefore, we took trimeric rhTau as 
the target to development a scFv specifically recognizes and captures it. Tested with 
AFM, immunoblotting assays and monoclonal capture ELISA assays, These scFvs (F9T, 
D11C and H2A) proved to recognize all forms of dimeric, trimeric and small oligomeric 
tau including those with typical sites phorphorylated tau found in AD pathology from 
AD-tau transgenic animal and AD human brain tissues. One could tell from Figure 5.1 
that F9T scFv and AT8 anti-phosphorylated-tau antibody detect distinct amount but 
different variants of tau in SHSY5Y-TMHT441 cells that expressing mutant human tau 
related to AD, while they failed to detect anything in wild type SHSY5Y. The detected 
tau in two images may have overlap but one would never know unless another small tau 
antibody is introduced in the test. Therefore, to confirm the abnormal tau species 
distinguished by trimeric tau scFvs are soluble oligomeric tau not fibrillar tau, we 
develop another group of scFvs targeting small molecular tau including monomer, dimer 
and oligomers, with the same biopanning protocol. These small tau scFvs (F3A, 3B5 etc.) 
are better detecting antibodies in our capture ELISA assays than commercial tau 
antibodies specific to a certain mutant hyperphosphorylated tau, because they are more 
specific to the tau monomeric and oligomeric structure instead of phosphorylation. It 
minimized the possibility that the toxic tau oligomeric captured by tau oligomer scFvs 
failed to be detected by the commercial antibody because of its lack of phosphorylation. 
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Such group of tau oligomers happens to be the one that is of most interest, as it is the 
evidence that pathological tau oligomers are not necessarily phosphorylated and the 
oligomeric structure of tau variants are of equal if not less critical factor than tau 
phosphorylated aggregates for AD pathogenesis and progression.  
We used the supernatant and cell lysate of both wild type and mutant htau 
expressing SHSY5Y to screening out anti-small-tau scFvs that can detect anti-trimeric-
tau scFv (i.e. F9T) targets, because these two neuronal cells prove to have a comparison 
of F9T targeted tau’s absence and presence. WX5, 3B5, 4H3 and F3A are four anti-
small-tau scFvs that can detect tau variants captured by F9T scFv (Figure 5.2) from the 
lysate of SHSY5Y-TMHT441 which contains highest concentration of F9T’s target 
(Figure 5.3). 
In the case of mutant human tau transgenic mice on the base of mouse tau 
knockout, we discovered that the abnormal tau oligomer level increase significant from 
3-month to 6-month in test group age, relative to negative control of each age group 
(Figure 5.4). We also identified F9T scFv’s target in the hippocampus section of single 
and repetitive mild TBI mice compared with none in that of control mice(Figure 5.5). 
These TBI mice prove to have chronic neuropathological and neurobehavioral changes 
[21, 25]. F9T scFv can also differentiate TBI rats as soon as 7 days after TBI treatments 
compared with negative control of each time frame (Figure5.6). Such rodent models 
without human tau transgenic suffered from traumatic brain injury (TBI) are good tools 
of studying tau oligomer’s role in TBI progression, although the animal tau is different 
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from human tau. It implicates tau oligomers as the early form of tau aggregation that 
possibly propels the aggregation process.  
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5.7 Figures and tables 
 
Figure 5.1 F9T and AT8 can identify different forms of tau in SH-SY5Y-TMHT441 neuroblastoma cells using 
immunofluorescence techniques. The remaining anti-oligomeiric tau antibody F9T was detected by successive 
coincubation with 9E10 c-Myc antibody produced in mice and Alexa Fluor® 488 Goat Anti-Mouse IgG (H+L) 
Antibody. AT8 was commercially produced in mouse and was detected directly by Alexa Fluor® 488 Goat Anti-Mouse 
IgG (H+L) Antibody, which was excited to emit fluorescent light of 515nm to 530nm (green).  The neuronal nuclei 
were counterstained with DAPI (blue). F9T and AT8 displayed no obvious affinity to non-differentiated neuroblastoma 
SHSY-5Y cells(A), while show strong yet different pattern and intensity of immunoreactivity to SH-SY5Y-TMHT441, 
which was transfected a stable mutant human gene to expresses hyperphosphorylated tau. Such hyperphosphorylated 
tau can exist in various forms like monomer, oligomer and mostly in higher degree aggregates, detectable by AT8 (B). 
On the other hand, F9T was screened and engineered with an enhanced specificity to oligomeric tau. Compared with 
AT8 staining pattern, F9T detected discreet spots in neuronal culture with higher intensity possibly due to the repetitive 
epitopes of F9T existing in one molecule of tau oligomer(C). 
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Figure 5.2 small tau targeting scFvs screening using capture ELISA with SHSY5Y-TMHT441 lysate as analyte. 
This high sensitive capture ELISA test was performed using F9T scFv as capture antibody, SHSY5Y-TMHT441 lysate 
as analytes and all obtained small tau targeting scFv-displayed phage as detecting antibody. Predicted according to the 
result in Figure 5.1, some abnormal small molecular tau will be captured by F9T and retain in the wells at the amount 
proportional to the applied neuron lysate concentration.  WX5, 3B5, 4H3 and F3A display a higher signal on original 
lysate than on 1/10 concentration lysate while others display no distinct difference. Therefore, these four clones are 
valid detecting antibodies to work with F9T scFv and most favorably D11C scFv in analyzing animal tissues possibly 
containing pathological oligomeric tau. 
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Figure 5.3 Affinity analysis of small tau targeting scFvs to SHSY5Y-TMHT441 and wild-type SHSY5Y lysate 
portion captured by F9T scFv. We selected 4 potential valid small tau targeting scFvs in the form of display phage to 
detect the tau species F9T scFv captures from SHSY5Y-TMHT441 lysate (shy-tau lysate), wild type SHSY5Y lysate 
(wt shy lysate), wild type SHSY5Y supernatant (wt shy sup), SHSY5Y-TMHT441 supernatant (shy-tau sup) and its 
original high protein supernatant. All four clones display a strong recognition of abnormal tau in SHSY5Y-TMHT441 
lysate while they reaction with the other three types of analytes are low, below the PBS negative control. 
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Figure 5.4 Mutant human tau knockin mouse (Tau406+/TauKO) at different ages have a varying oligomeric tau 
amount compared with negative control(Tau406-/TauKO).  The high sensitivity capture ELISA was performed 
with F9T scFv as capture antibody and F3A phage as detecting antibody to investigate mutant human tau transgenic 
mouse brain on the correlation of oligomeric tau concentration and mouse age indirectly indicating tau-related AD 
pathology development. The signals of test group (Tau406+/TauKO) are displayed as the relative value of the signals 
of negative control group (Tau406+/TauKO) of corresponding ages.   
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Figure 5.5 F9T scFv detects abnormal tau lesion in hippocampal sections of wild type mice after single or 
repetitive traumatic brain injuries. Mice are of two independent groups (top and bottom) of which TBI mice brain 
has strong immunoreativity with F9T scFv compared with the control mice, reacted with 9E10 anti-cmyc IgG produced 
in mouse, anti-mouse IgG conjugated with HRP, which was chromogenic detected by 3,3'-diaminobenzidine 
tetrahydrochloride(DAB). (s-single; r-repetitive; sham-anesthesia control; mTBI-mild traumatic brain injury; scale 
bar=50µm) 
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Figure 5.6 Plots of affinity difference of F9T to TBI mice in different brain regions and different time after TBI 
treatment. The high sensitivity capture ELISA was performed with F9T scFv as capture antibody and 3B5 phage as 
detecting antibody to investigate TBI mice brain and its abnormal tau concentration with similar structure with human 
tau oligomers. All signals of test cases are relative to the sham control of sham negative control of each brain sections, 
which are set as 1. 
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Chapter 6 Proposed future work 
6.1 Introduction 
The incidence of Alzheimer’s disease doubles every five years after the age of 65. By the 
age of 85, nearly 50% of people still alive have AD. This fact is critically important in the 
United States since the baby boomers have entered this AD high-risk age range and the 
total number of AD patients in US will grow rapidly. Therefore, a reliable and convenient 
diagnostic approach for preclinical AD and mild cognitive impairment (MCI) is in dire 
need. Antibody fragments such as scFvs that can selectively detect the presence of 
protein variants associated with AD in patient tissue or fluid samples are a promising tool 
to facilitate early and accurate diagnoses of AD. scFvs have been developed against a 
variety of different protein targets involved in neurodegenerative diseases and shown to 
have diagnostic and therapeutic value. We expect that the tau trimer targeting scFvs 
isolated in this study will be similarly useful for helping to define the role of soluble 
aggregated tau in neurodegenerative disease.  
The hallmark extracellular senile plaques and intracellular neurofibrillary tangles 
(NFTs) of AD were first discovered by Dr. Alois Alzheimer more than a century ago and 
have been the definition of the disease thereafter. Much effort has been made to detect 
and quantify the presence of these plaques and tangles in brain tissue in vivo. For 
example, Amyvid, a drug approved by US FDA recently, is a radioactive dye capable of 
staining amyloid plaques on a PET scan[1]. However, many studies indicate oligomeric 
amyloid or tau are the more toxic species and are the precursors of the insoluble plaques 
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and tangles[2-5]. Rather than detecting the plaques and tangles, a more reliable and 
earlier diagnosis might be facilitated by identifying and quantifying the presence of key 
oligomeric protein species.  Determining the levels of oligomeric tau present in brain 
tissues including cortex, hippocampus and CSF could be a very useful tool to facilitate 
early and accurate diagnoses of AD or other dementias.  
In addition to AD, tau pathology is present in other neurodegenerative diseases 
including Parkinson’s disease (PD), frontotemporal dementia with Parkinsonism (FTDP-
17) and progressive supranulear palsy (PSP). Tau lesions are also a major feature in 
repetitive closed head injury including chronic traumatic encephalopathy (CTE)[6] that 
commonly happens to professional athletes engaging in contact sports such as football[7] 
or boxing[8-9]. A recent study using an aged mouse model expressing human tau 
suggests that repetitive mild traumatic brain injury can augment tau pathology and glial 
activation based on the presence of hyperphosphorylated or aggregated tau in mouse 
brain sections [10]. Since we can selectively detect the presence of oligomeric tau, we 
would like to determine if oligomeric tau is an early marker of brain injury using a mouse 
model that undergoes single or repetitive traumatic brain injury. We propose that F9T has 
the potential of recognizing abnormal tau intermediate forms in brain section and thusly 
diagnosing tau induced brain damage at its early stage. 
As demonstrated in Chapter 3, trimeric tau species of either 2N4R or 1N4R 
displayed higher toxicity when applied extracellular than tau monomer, dimer and 
expectedly PBS negative controls. We observed that the rhTau stably transfected SHSY-
5Y-TMHT441[11] generally grows slower and displays early apoptosis compared with 
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its wild-type form SHSY-5Y neurons. These results suggest that tau oligomers may be 
responsible of propagating tau lesions and impairing the host neuron physiological 
functions[12-13]. By adding scFvs that selectively target tau oligomers to cultured 
neuronal cells and measuring the difference of neurotoxicity or viability compared to 
controls, we can better understand how scFv would affect its targets, i.e. tau oligomers, 
and tau-induced toxicity. 
Although there is no direct evidence of cause-effect relations between AD 
development with tau polymerization and aggregation, time correlation of tau 
aggregation with the neurodegeneration process has been observed as that of Aβ.  scFv 
targeting tau oligomers would be of great value if it’s tested and proved to bear negative 
influence on tau oligomer formation or aggregation.  
6.2 Material and methods 
Preparation of human tau- Tau was purified from the cortex of a 44 year old male with 
severe Familiar Alzheimer’s Disease with tau pathology (AD tau) characterized by 
numerous argyrophilic neuronal tangles (Bielschowsky staining), and innumerable AT8-
labeled neurons present throughout the cerebral cortex including the motor cortex (BA4), 
and visual cortex (BA17). Tissue was provided by the New York Brain Bank – The Taub 
Institute, Columbia University. This tissue was prepared as previously 
described[14][14]with the modification that size fractionation was used in place of the 
immunoaffinity column for the final purification step. An advantage of this method is that 
tau phosphorylation is preserved using homogenization buffer containing 1% perchloric 
121 
acid. Reductant was used during purification and fractions containing monomeric tau 
were pooled, concentrated and buffer exchanged into 50 mM Tris-HCl pH 7.4.  
Atomic Force microscopy (AFM)- For AFM sample preparation, a 10 μl aliquot of 10 
μg/μl Tau protein solution was deposited on a freshly cleaved mica substrate (Spruce 
Pine, NC), incubated for 5 min at room temperature, rinsed extensively with 0.2 μm 
filtered deionized water (18.1 MΩ, Millipore, MA), and dried under a gentle stream of N2 
gas. All AFM height images were recorded in tapping mode with scan rates of 2.5 Hz and 
512x512 pixels resolution with commercial AFMs in air at room temperature. AFM 
images for height distribution calculations were acquired using the Nanoscope IIIa AFM 
(Veeco, Santa Barbara, CA) equipped with oxide sharpened Si3N4 AFM tips (k = 40 
N/m, fo ~ 300kHz) (Model: OTESPA, Veeco, Santa Barbara, CA) and analyzed with the 
Scanning Probe Imaging Processor software (SPIP, Image Metrology) in order to reduce 
the effect of bowing and tilt mica surface on background, a second-order polynomial 
flattening was performed.  
Height Distribution Analysis- The AFM files of each Tau sample can be analyzed to 
generate the particle height distribution with Gwyddion. The flattened background of 
each image was set to zero, and every detected particle on the imaged was categorized 
according to its size determined by pixels on the AFM image. A statistical analysis of the 
particle height distribution was also generated by Gwyddion. The particle counts were 
added up within each height range. The total number of the particles in the image was 
also calculated, and depends on the image size and sample concentration. Therefore, the 
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percentage of particles in certain height range taking up of the total number can represent 
the distribution. It also makes it convenient to compare between different samples. 
Cell culture and treatments- SHSY5Y-TMHT441 cells was designed and provided by Dr. 
Birgit Hutter-Paier group in QPS, Austria. The cells was transfected with stable mutant 
human tau to express tau phosphorylated at AD-related sites[11]. It was cultivated using a 
revised protocol based on that of cultivating SHSY5Y human neuroblastoma cell lines 
(American Tissue Culture Collection)[15]. The culture medium contains 44% v/v Ham’s 
F-12 (IrvineScientific), 44% v/v MEM Earle’s salts (IrvineScientific), 10% v/v denatured 
fetal bovine serum (FBS) (SigmaAldrich), 1% v/v MEM non-essential amino acids 
(Invitrogen), 1% v/v antibiotic/antimycotic (Invitrogen), and additional 300 μg/mL 
Geneticin G-418 for first few reviving passages.  
Immunocytofluorescent staining- The human neuroblastoma cells SHSY5Y wild-type and 
human mutant tau transfected type (SHSY5Y-TMHT441) were seeded and cultured in 8-
well chamber for 24 h. Cells were washed with PBS buffer and then fixed with 4% PFA. 
Cells were incubated with polyclonal rabbit antibody against human tau (Catalog: PA1-
18272, Thermo-scientific, 1:400), or scFv against tau oligomers (D11C and F9T scFv 
with tag c-Myc) overnight in 4oC.  The rabbit anti-c-myc antibody (Abcam, 1:1500) was 
followed and then fluorescent goat anti-rabbit IgG were applied for 30 min. 
Oligomeric tau toxicity assay- SHSY5Y-TMHT441 is cultivated and plated as described 
previously[15]. Different concentrations of anti-oligomeric tau and control scFvs will be 
added to cells.  Cell toxicity and viability will be measured using LDH assay[15-17]. 
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scFv effects on extracellular tau induced neurotoxicity- We will determine whether the 
anti-oligomeric tau scFvs can block spread of toxicity induced by different tau variants.  
We will add samples containing various tau forms to SH-SY5Y cells with or without 
added scFv.  Sample to be tested will include supernatant and cell lysates from tau 
overexpressing Sh-SY5Y cells and brain homogenates from AD mouse models and post-
mortem human AD and control tissue. Toxicity will be monitored by LDH assay as 
described[15].  
6.3 Preliminary results and future work plan  
6.3.1  Preliminary diagnosis of  AD using AFM and size distribution  
AFM has been long used to investigate material morphological features at molecular 
level including biomolecules. In our study, it also plays an important role in preliminary 
diagnosis of AD based on the analysis result of tau aggregation conditions. The healthy 
control human brain contains normal monomeric tau only that displayed as a single peak 
at 1.5nm to 2.0nm, while the AD human brain contains monomeric, dimer, trimer and all 
types of oligomers of different isoforms that displayed as multiple peaks including HC 
peak as the lowest MW(Figure 6.1A). Due to the different isoforms at different 
oligomeric level, the molecular weights at the peaks in AD combined curve are hard to 
interpreted or defined. However, the bright side is that a healthy human brain contains 
only monomeric tau falls in a small MW range for all isoforms. We can use it as a 
calibration (Figure 6.1B) to diagnose if the patient is healthy or inclined to develop AD. 
As this technique matures similar as mass spectrometry did, we can know more about the 
tau contents and their features in AD. 
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6.3.2  Detection of tau oligomers in tissue implies early diagnostic potential  
We will assay human CSF and serum samples for the presence of oligomeric tau using 
the anti-oligomeric tau scFvs.  Preliminary data generated using AFM to image binding 
of anti-oligomeric tau scFvs displayed on the surface of a phage particle to post-mortem 
human CSF samples indicate that we can detect oligomeric tau in CSF samples.  
Although AFM based F9T phage affinity test assay is a promising tool for detecting the 
presence of low concentrations of target antigens in human samples, we have developed a 
sensitive capture ELISA in our lab which facilitates analysis of multiple samples.  We 
will use this capture ELISA to analyze post-mortem human CSF and serum samples.  
Another effective way of tau oligomer detection at cellular-level is 
immunocytofluorescence assay. Tau oligomers were targeted and bound by F9T scFv in 
SHSY5Y cells transfected with human mutant tau (Figure 6.2). The results showed a 
negative immunostaining of total tau (A) and Oligomer Tau with clone D11C (B) and 
clone F9T (C) in SH-SY5Y cells. However, in SHSY5Y-TMHT441, the immunopositive 
staining were observed with total tau (D) and oligomeric tau aggregates (arrows in E and 
F, clone D11C and F9T, respectively). 
We have also shown in Chapter 5 that oligomeric tau is selectively present in 
single and repetitive mild TBI mouse hippocampus sections using immunohistochemcal 
staining suggesting that oligomeric tau is a promising biomarker for patients suffering 
from TBI and CTE. F9T also target a much younger sacrificed TBI rats from negative 
controls. We will analyze various different brain samples from mice that have suffered 
TBI to determine the time course profile of oligomeric tau following traumatic brain 
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injury. We will also assay CSF samples taken from patients suffering TBI in 
collaboration with Dr. Leslie Baxter and Dr. Nicholas Theodore (Barrow Neurological 
Institute).  
6.3.3  Therapeutic potential of anti-oligomeric tau scFvs 
The anti-oligomeric tau scFv, F9T,  shows strong immunoreactivity with the tau 
expressing neuron model SHSY-5Y-TMHT441 but essentially no reaction with wild-type 
SHSY-5Y(Figure 6. 2 (A) versus (C)).  The monoclonal antibody AT8 which binds 
phosphorylated aggregates of tau also preferentially stains SHSY-5Y-TMHT441 cells 
(Figure 6. 2 (B)), although with a different pattern than that observed with F9T.  We 
hypothesize that scFv targeting tau oligomers can ameliorate neurotoxicity induced by 
either extracellular or endogenous aggregates of tau. We will determine whether the anti-
oligomeric tau scFvs can block tau induced toxicity by adding cell supernatant and lysate 
samples from the tau overexpressing SHSY-5Y-TMHT441 cells to healthy SHSY-5Y 
cells.  We will add different concentrations of anti-oligomeric tau scFv to the samples to 
determine how efficiently the scFvs can block tau induced toxicity. We will perform 
similar studies with brain homogenates from different AD mouse models and from post-
mortem human AD tissue to determine whether the scFvs can block spread of tau toxicity 
from brain samples as well.   
These studies should demonstrate whether the anti-oligomeric tau scFvs isolated 
here have potential diagnostic and therapeutic value for neurodegenerative diseases 
including AD, TBI and other tauopathies.    
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6.4 Figures and tables 
 
 
Figure 6. 1 Human brain derived tau analyzed by AFM on the particle size distribution. (A) Size distribution 
results of four Alzheimer’s (AD) patients and five healthy control (HC) human cases separately; (B) Size distribution 
results of combined AD and HC human groups. The HC human brain contains normal monomeric tau only that 
displayed as a single peak at 1.5nm to 2.0nm, while the AD human brain contains monomeric, dimer, trimer and all 
types of oligomers of different isoforms that displayed as multiple peaks including HC peak as the lowest MW. 
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Figure 6. 2 Tau oligomers observed by F9T and D11C scFv in SHSY5Y-TMHT441 expressing mutant human 
tau. SHSY5Y(A,B,C) and SHSY5Y-TMHT441(D,E,F) were seeded and cultured in 8-well chamber for 24 h. Cells 
were washed with PBS buffer and then fixed with 4% PFA. Cells were incubated with polyclonal rabbit antibody 
against human tau (Catalog: PA1-18272, Thermo-scientific, 1:400) targeting all tau (A and D), or scFv against tau 
oligomers overnight in 4oC.These tau oligomer targeting scFv are tagged with c-myc and named as D11C (B and E) 
and F9T (C and F).  The rabbit anti-c-myc antibody (Abcam, 1:1500) was followed and then fluorescent goat anti-
rabbit IgG were applied for 30 min. Goat anti-rabbit IgG was commercially produced in mouse and was detected 
directly by Alexa Fluor® 488 Goat Anti-Mouse IgG (H+L) Antibody, which was excited to emit fluorescent light of 
515nm to 530nm (green). The neuronal nuclei were counterstained with DAPI (blue). This figure showed a negative 
immunostaining of total tau (A) and oligomer tau with clone D11C (B) and clone F9T (C) in SHSY5Y cells. However, 
in SHSY5Y-TMHT441 expressing human mutant tau, the positive immunostaining were observed with total Tau (D) 
and oligomer tau aggregates (arrows in E and F, clone D11C and F9T, respectively).  
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